Podcast appearances and mentions of John Cleland

Escritor, professor e realizador português, habitante do mundo. Um homem que abre o coração nesta partilha que nos leva da ficção para a realidade. Recomendo ouvirem esta conversa, vale a pena.Os livros que o Possidónio escolheu:A Lírica de Camões;Fanny Hill - Memórias de uma Prostituta, John Cleland;O Estranho Mundo de Garp, John Irving;A série Ripley, Patricia Highsmith;A Obra ao Negro, M. Yourcenar.Outras referências:Enid Blyton;Tarzan e John Carter, Edgar Rice Burroughs;Poema do Rui Belo: O Portugal Futuro;John Irving:A Última Noite Perto Do Rio;As Regras Da Casa Da Sidra.Eu estou aqui, Nina LaCour;Memórias de Adriano, Marguerite YourcenarAgustina Bessa-Luís;Admirável Mundo Novo, Aldous Huxley.Alguns dos que escreveu:Materna Doçura;O Mar Por Cima;A Vida Sonhada das Boas Esposas;A Selva Dentro de Casa.O que ofereci:Sangue do meu sangue, Michael Cunningham.Os livros aqui:www.wook.pt

In this episode, Asante Tracey speaks with ACTRA Toronto Executive Councillor and AI Subcommittee Co-Chair John Cleland about the critical implications of artificial intelligence (AI) in the entertainment industry. They discuss two key types of AI affecting performers: digital replicas and generative AI, and John highlights concerns such as the lack of consent protections, control over biometric data, and inadequate compensation for AI use. Further, John stresses the importance of ACTRA Members educating themselves, advocating for legislative protections, and actively participating in union efforts to address these challenges.

In the second episode in a four-part series, Dre Harrison introduces another interview from Super Touring Power 2, the event that celebrated what many fans consider to be the golden era of Touring Car racing.  In Episode 2, Kevin Turner sits down with two legends of the sport and beyond; 1993 British Touring Car Championship Runner-Up Steve Soper, and two-time British Touring Car Champion in 1989 and 1995, John Cleland. In the episode, Kevin presses Steve and John on the strengths and weaknesses of their cars in a highly competitive environment (Including the startling revelation that Cleland hated front-wheel drive!), dealing with the rise of popularity the series had in the '90s, and asking if there was one Super Touring Car they always wanted to drive, but never did… Learn more about your ad choices. Visit podcastchoices.com/adchoices

Today, we have the legend that is John Cleland.  Double BTCC Champion, and one of the most competitive racers to come from Scotland.  He reveals his intense moments of touring car battles with famous rivals that you won't hear anywhere else!   John is a commanding driver, a man of his word and successful business and family man.  I'm sure you'll enjoy the interview.   Have a great week   Hugh

Our special episodes from Brands Hatch continue, as Alex and Greg Haines sit down for a brilliant chat with touring car legend, Steve Soper. Steve tells us all about his career with BMW, battles with Rouse, the end of his career with Peugeot and of course, that infamous incident with John Cleland in the 1992 BTCC title decider!Support the Show.GET IN TOUCH: Use the hashtag #SuperTouringPod on X or email pod@1990sbtcc.com or you can send us a text message!Follow @SuperTouringPod on Instagram & X.

To many, it was the greatest era of Touring Car racing ever seen, and a regulation set that became the blueprint for saloon racing all over the world. But just what is the greatest Super Touring car of them all? Joining Kevin Turner on the Autosport Podcast is the current British Touring Car Championship commentary pair of David Addison and Tim Harvey and together they rank the 10 greatest Super Touring Cars of all time. Amongst them, some heavy debate - Was the Vauxhall Cavalier the product of John Cleland's greatness as a driver? Does the Renault Laguna crack the Top 5 with its domestic success? Where does the Ford Mondeo end up despite its late arrival? And where does the legendary Alfa Romeo 155 end up due to Gabriele Tarquini's legendary 1994? Let us know in the comments what you think the greatest Super Tourers are and listen in! Learn more about your ad choices. Visit podcastchoices.com/adchoices

Innovation can pose a lot of challenges to the public sector. How can state government innovate at the pace of industry? When new technologies can pose a risk as much as an opportunity, how can government respond with innovation in risk-adverse environments? What does it mean to lead innovation strategies from the ground-up?   In four short stories from across NSW, hear how leadership is working collaboratively across government, responding to the changing expectations of customers and taking innovative solutions from the frontline to scale organisation-wide.   Andrew George, Chief Executive Officer, WaterNSW Megan Stiffler, Deputy Commissioner, Fire & Rescue NSW John Cleland, Chief Executive Officer, Essential Energy Alexandra Geddes, Executive Director, Programs & Innovation, NSW Environment Protection Authority.   For more great insights head to www.PublicSectorNetwork.co  

This week, the guys are joined by BTCC legends John Cleland & Anthony Reid who preview the forthcoming Super Touring Power festival at Brands Hatch. We are also joined by the organisers of the event, David Willey & Stuart Caie as the sound of Super Tourers once again grace the Brands Hatch circuit at the end of June. David & Stuart tell us everything about the event, whilst John and Anthony reminisce about their times racing super tourers around Brands Hatch, with their own unique stories!Support the Show.GET IN TOUCH: Use the hashtag #SuperTouringPod on X or email pod@1990sbtcc.com or you can send us a text message!Follow @SuperTouringPod on Instagram & X.

Joining Alex, Adam & Levi this week is commentator Barry Nutley, to look back at an exciting race meeting at Thruxton in 1997 - a race Barry commentated on for the BBC. We dive into the controversial collision between Audi team mates Bintcliffe & Biela, the drivers reactions to the 'dangerous' conditions, the drama in the pitman and yet another collision between Tim Harvey and John Cleland!This was also the closest Peugeot ever got to taking a BTCC victory, we look into just how close it was!GET IN TOUCH: Use the hashtag #SuperTouringPod on X or email pod@1990sbtcc.comFollow @SuperTouringPod on Instagram & X.

In Chapter 8 of "Fanny Hill: Memoirs of a Woman of Pleasure" by John Cleland, the protagonist Fanny Hill continues her narrative sharing erotic tales and experiences. In this chapter, Fanny recounts further episodes from her life, delving into the explicit and sensual aspects of her journey. John Cleland's work is renowned for its detailed and provocative descriptions of sexual encounters, exploring themes of desire, pleasure, and the complexities of human sexuality. The Tale Teller Club functions as a narrative device that contextualizes Fanny's story within the broader theme of erotic literature, providing readers with a glimpse into the intimate and passionate aspects of Fanny's life.

The novel follows the life of Fanny Hill, a young woman who enters the world of prostitution in 18th-century London. Each chapter recounts various episodes and experiences in Fanny's life, exploring themes of love, desire, and societal expectations.

"Fanny Hill: Memoirs of a Woman of Pleasure" is an 18th-century erotic novel written by John Cleland. It was first published in 1748 and is one of the earliest examples of erotic literature in English. The novel is structured as a series of letters from the titular character, Fanny Hill, to an unnamed recipient, recounting her life experiences.The story follows Fanny Hill, an orphan, as she navigates the world of 18th-century London. After arriving in the city, Fanny is introduced to the world of prostitution, and the novel chronicles her various encounters and relationships in explicit detail. Despite the explicit content, Cleland's work also explores themes of love, desire, and the complexities of human sexuality.Throughout the novel, Fanny evolves as a character, and her experiences provide a glimpse into the social and moral landscape of the time. The narrative addresses the moral and social implications of Fanny's choices and challenges prevailing norms regarding sexuality."Fanny Hill" is celebrated for its literary style and its historical significance as an early work of erotic literature. While it was initially banned and considered scandalous, it has since been recognized as an important piece of literature that reflects the cultural attitudes of its time.

"Fanny Hill: Memoirs of a Woman of Pleasure" is an 18th-century erotic novel written by John Cleland. In Chapter 6, Fanny Hill continues her narrative within the Tale Teller Club, a fictional literary society. The club provides a platform for individuals to share their erotic experiences and adventures. In this chapter, Fanny recounts her own experiences, delving into the sensuous and provocative aspects of her life. Cleland's work is known for its explicit and detailed descriptions of sexual encounters, exploring themes of desire, pleasure, and the complexities of human sexuality. The Tale Teller Club serves as a narrative device to frame Fanny's story and contextualize it within the broader theme of erotic literature.

Hand chosen books by Sarnia de la Maré FRSA, founder of Tale Teller Club Publishing.www.sarniadelamare.blogspot.com fo more information and reading material.

www.taletellerclub.com

www.taletellerclub.comThe best classic books at the Tale Teller Club£bannedbooks

Our featured book at www.iservalan.com#bannedbooks

www.iservalan.com#bannedbooks#taletellerclub

Fanny Hill: Memoirs of a Woman of Pleasure by John ClelandPublication date 2006-01-04 Usage Public Domain Topics #librivox, #literature, #audiobook, #erotica, #banned #books, Language #EnglishLibriVox recording of Fanny Hill, Memoirs of a Woman of Pleasure by John Cleland.Fanny Hill: Memoirs of a Woman of Pleasure (1749) was the first widely-read English novel in the genre "Erotica." It was written by John Cleland as he was serving hard time at a debtor's prison in London. Over the centuries, the novel has been repeatedly banned by authorities, assuring its preeminent role in the history of the ongoing struggle against censorship of free expression.Until Fanny Hill, previous heroines had conducted their amorous liaisons "off-stage." Any erotic misadventures were described euphemistically. As women who had gone astray, they always repented, which made even their most outrageous dalliances somehow suitable for a moralistic readership. The protagonist of Fanny Hill, however, never repented a single moment of her sexual exploits ... quite the contrary! And with Fanny, the devil is in the details, realistically described. (Summary by Denny Mike)

This week, the guys are looking back at the biggest rumours and entries that never came to fruition, looking at the possible Mercedes factory team, Gareth Howell's various attempts at entering the BTCC and Alain Prost's chances of racing for Renault...With insights from David Coulthard, John Cleland, Patrick Watts and Ian Flux.GET IN TOUCH: Use the hashtag #StoriesFromSuperTouring on Twitter and Facebook or email pod@1990sBTCC.com

CME credits: 0.25 Valid until: 01-12-2024 Claim your CME credit at https://reachmd.com/programs/cme/addressing-issues-of-cv-mortality-in-clinical-trials-with-iv-iron-are-we-still-getting-a-medical-benefit/15333/ Iron deficiency is a common heart failure comorbidity with a negative impact on patients' quality of life and mortality. Recent world events may have influenced clinical trial outcomes with IV iron in heart failure, and secondary analysis has become commonplace. Are the findings still clinically relevant, and are we still getting a clinical benefit? Join Drs. Stefan Anker, Piotr Ponikowski, and John Cleland as they differentiate the design of IV iron trials and break down the relevance of key clinical endpoints. Are we still asking the right questions? =

In the latest episode of our CEO Viewpoints podcast series, host James McLean sits down with John Cleland, CEO of Australia's Essential Energy. This year, the annual CEO survey focuses on critical questions facing leaders today including how to balance reinventing the business to succeed in a changing world with the need to manage short-term pressures and challenges. In the podcast discussion John shares his experiences and learnings of leading and accelerating a utility through the energy transition, balancing customer and stakeholder expectations, his commitment to sustainable and safe energy, and his outlook on where the sector is headed.(00:01)- James's introduction to CEO Viewpoints and John Cleland(01:34)- John shares more about his career background so far(03:02)- John explains more about Essential Energy in terms of scale, customers and employees(04:29)- John shares more about what enticed him towards his current role(06:49)- John explains some of the challenges he's faced along the way in his role, and how he's navigated those challenges(11:18)- John explains the implications of the major cultural and digital changes that have taken place in recent years(13:32)- John explains how the company's recruitment strategy has evolved over time(15:17)- John sheds light on his stakeholder management strategy(17:59)- John shares some of the critical investments and surprises along the way during the company's transformation(22:53)- John explains how the company is being cost-effective while still innovating(25:50)- John shares some of the things he might have done differently when looking at the journey in hindsight(28:13)- John and James share their closing thoughts and conclusions

This week, Al, Adam and Levi are joined by motoring and touring car journalist Andrew Charman, to take a look back at one of the most controversial championship deciders in the history of motorsport, with some insights from John Cleland.GET IN TOUCH: Use the hashtag #StoriesFromSuperTouring on Twitter and Facebook or email pod@1990sBTCC.com Hosted on Acast. See acast.com/privacy for more information.

This week, Al & Levi are joined by former BTCC driver Adam Jones & BRSCC commentator Scott Woodwiss to look back at Yvan Muller's first ever BTCC victory at Brands Hatch in 1999. They also look back at the other stories of the weekend, including Aiello losing out on winning £250,000 from TOCA and John Cleland's 200th BTCC race start. GET IN TOUCH: Use the hashtag #StoriesFromSuperTouring on Twitter and Facebook or email pod@1990sBTCC.com Hosted on Acast. See acast.com/privacy for more information.

We're talking to John Cleland on this week's episode of the V8 Sleuth Podcast. In the last part of a two-part chat, John talks about his love affair with Australia, Mount Panorama and the Bathurst 1000. It's been 30 years since his first trip to race in the Great Race, and he recounts tales from racing with Peter Brock (and how he came to race one of the Holden Dealer Team ‘Last of the Big Banger VKs in England) and his first experience of a V8 touring car at Mount Panorama, to finishing on the podium with Brad Jones, and the time he ended up on his roof in one of Brad Jones' cars after hitting Peter Brock's car! He also tackles your National Motor Racing Museum Couch Racer Questions. V8 Sleuth Superstore >> https://superstore.v8sleuth.com.au/

We're talking to John Cleland on this week's episode of the V8 Sleuth Podcast. In the first part of a two-part chat, John talks about how he got into the sport in the first place and the deal he cut with his car dealer dad to go racing, watching his hero Jim Clark debut the iconic Lotus 49 and Ford Cosworth DFV at the 1967 Dutch Grand Prix and what it means to him to have his name alongside Clark's on the British Touring Car Championship trophy. He also talks about how his long relationship with Vauxhall and General Motors first came about, the cheeky bit of gamesmanship that helped him win the 1989 BTCC, how he feels nowadays about that controversial 1992 title decider, which of his BTCC rivals was the most fun to wind up and the time BTCC chief Alan Gow squared him up for a prank. John also talks about seeing the clear benefits of motorsport to the brands his car dealership sold, the ex-Peter Brock car that he now owns, and why he retired from racing full-time at the end of 1999. V8 Sleuth Superstore: https://superstore.v8sleuth.com.au/

John Cleland is Co-founder and CEO of RenewWest, an environmental asset developer that addresses climate change through the development of natural working land emission reduction projects. https://www.renewwest.com/ https://nexuspmg.com/

On this week's episode of Currently Reading, Meredith and Kaytee are discussing: Bookish Moments: reading mojo and a package of bookish delights Current Reads: all the great, interesting, and/or terrible stuff we've been reading lately Deep Dive: how do we decide which books to own or keep? The Fountain: we visit our perfect fountain to make wishes about our reading lives As per usual, time-stamped show notes are below with references to every book and resource we mentioned in this episode. If you'd like to listen first and not spoil the surprise, don't scroll down!  We are now including transcripts of the episode (this link only works on the main site). The goal here is to increase accessibility for our fans! *Please note that all book titles linked below are Bookshop affiliate links. Your cost is the same, but a small portion of your purchase will come back to us to help offset the costs of the show. If you'd prefer to shop on Amazon, you can still do so here through our main storefront. Anything you buy there (even your laundry detergent, if you recently got obsessed with switching up your laundry game) kicks a small amount back to us. Thanks for your support!*   . . . . 1:21 - Bookish Moment of the Week 3:15 - Parnassus Books 3:34 - Currently Reading Patreon (supporters get access to the IPL each month) 4:16 - Fabled Bookshop 5:32 - The Vaster Wilds by Lauren Groff (Publishes Sept 2023) 7:09 - Current Reads 7:23 - To Catch a Raven by Beverly Jenkins (Kaytee) 7:32 - Rebel by Beverly Jenkins  11:30 - A Court of Silver Flames by Sarah J. Maas (Meredith) 16:46 - A Court of Thorns and Roses by Sarah J. Maas 18:11 - Beach Read by Emily Henry 18:54 - The Storyteller's Death by Ann Davila Cardinal (Kaytee) 19:06 - Schuler Books 21:10 - The Last Cuentista by Donna Barba Higuera 21:46 - The Agathas by Kathleen Glasgow (Meredith) 23:28 - Truly Devious by Maureen Johnson 25:08 - Diving In Podcast 25:37 - The Taking of Jake Livingston by Ryan Douglass (Kaytee) 25:43 - Changing Hands Bookstore 30:27 - The Future is Yours by Dan Frey (Meredith) 34:05 - How Books Make It To Our Forever Shelves 38:19 - The Shell Seekers by Rosamund Pilcher 38:20 - Count of Monte Cristo by Alexandre Dumas 38:22 - A Gentleman in Moscow by Amor Towles 38:25 - Search by Michelle Huneven 39:53 - Scythe by Neal Shusterman 41:41 - The Home-Maker by Dorothy Canfield 42:46 - Still Life by Louise Penny  43:13 - Babel by RF Kuang 46:15 - Meet Us At The Fountain 46:42 - I wish everyone would read Ex Libris: Confessions of a Common Reader by Anne Fadiman in a Specific Way (Kaytee) 46:42 - Ex Libris: Confessions of a Common Reader by Anne Fadiman 47:01 - Fanny Hill by John Cleland 49:04 - Pango Books 49:14 -  I wish I liked putting together Ikea furniture (Meredith) 49:24 - Ikea full size Billy Bookcase Connect With Us: Meredith is @meredith.reads on Instagram Kaytee is @notesonbookmarks on Instagram Mary is @maryreadsandsips on Instagram Roxanna is @roxannatheplanner on Instagram currentlyreadingpodcast.com @currentlyreadingpodcast on Instagram currentlyreadingpodcast@gmail.com Support us at patreon.com/currentlyreadingpodcast and www.zazzle.com/store/currentlyreading

Memoirs Of Fanny Hill A New and Genuine Edition from the Original Text (London, 1749)

Steve Rider is a bona fide legend of British sports broadcasting. Talking Away in this episode, the BBC Grandstand turned ITV Sport anchorman has been there and done it in just about every sport imaginable. There's plenty of nostalgia as Steve recalls the highest high of Lewis Hamilton winning the 2008 F1 world title on the last corner of the last lap of the last race and the lowest low of 3-time World Champion Ayrton Senna losing his life live in-vision at the 1994 San Marino Grand Prix. There's also discussion on Steve's invaluable contribution to the development of TV coverage for the British Touring Car Championship, including memories of the late Murray Walker and a clip from the great man's first-ever BBC broadcast in 1949.Follow @GregHainesTV on social media!X - https://x.com/greghainestvInsta - https://www.instagram.com/greghainestvYouTube - https://www.youtube.com/greghainestvContact Talking Away by email:TalkingAwayPodcast@gmail.com

Dans cette émission, nous nous intéressons au monde de la prostitution. Celle-ci tout au long de l'histoire et plus particulièrement au XIXe siècle change de statut et de nature ; elle s'amplifie, trouble et inquiète ceux investis de la mission de veiller au bon ordre social. Système complexe, elle est protéiforme tant au niveau des profils que des lieux où elle s'exerce. Dans ce premier volet, nous allons nous pencher sur la mise en place de la surveillance de ce monde et sur la vie quotidienne des bordels. Extrait : Liste d'expressions, Les folles d'enfer de la Salpetrière de Makhi Xenakis, Dénonciation de Mme Doshmont, Les illusions perdues de Balzac, description guide rose, Fanny Hill de John Cleland, Décorium de Chabannais, Portrait de la maquerelle Mme Paris, Le pornographe de Restif de la Bretonne Musique : Quand j'entends les gens de Mélodie Lauret, Hot mess de Girli, Easy de My art

This week - Al, Levi & Producer Dan are joined by touring car royalty, as John Cleland drops in for a chat & talks all things BTCC. Despite lots of talk about on track activities, we all cover the many pranks that went on in the paddock, the time John accused the Race Director of being high on drugs & how Nigel Mansell still recalls to him their Donington 1998 battle every time their paths cross.GET IN TOUCH: Use the hashtag #StoriesFromSuperTouring on Twitter and Facebook or email pod@1990sBTCC.com Hosted on Acast. See acast.com/privacy for more information.

Septiembre 1. Tom Jones – Henry Fielding 2. Fanny Hill: Memorias de una cortesana – John Cleland --- Send in a voice message: https://anchor.fm/irving-sun/message

An obscenity is any utterance or act that strongly offends the prevalent morality of the time. It is derived from the Latin obscēnus, obscaenus, "boding ill; disgusting; indecent", of uncertain etymology. The word can be used to indicate strong moral repugnance and outrage, in expressions such as "obscene profits" and "the obscenity of war". As a legal term, it usually refers to graphic depictions of people engaged in sexual and excretory activity, and related utterances of profane speech. United States obscenity law. In the United States, issues of obscenity raise issues of limitations on the freedom of speech and of the press, which are otherwise protected by the First Amendment to the Constitution of the United States. Federal obscenity law in the U.S. is unusual in that there is no uniform national standard. Former Justice Potter Stewart of the Supreme Court of the United States, in attempting to classify what material constituted exactly "what is obscene," famously wrote, "I shall not today attempt further to define the kinds of material I understand to be embraced ... but I know it when I see it...." In the United States, the 1973 ruling of the Supreme Court of the United States in Miller v California established a three-tiered test to determine what was obscene—and thus not protected, versus what was merely erotic and thus protected by the First Amendment. Delivering the opinion of the court, Chief Justice Warren Burger wrote: The basic guidelines for the trier of fact must be: (a) whether the average person, applying contemporary community standards, would find that the work, taken as a whole, appeals to the prurient interest, (b) whether the work depicts or describes, in a patently offensive way, sexual conduct specifically defined by the applicable state law; and (c) whether the work, taken as a whole, lacks serious literary, artistic, political, or scientific value. Non image-based obscenity cases in the U.S. While most recent (2016) obscenity cases in the United States have revolved around images and films, the first obscenity cases dealt with textual works. The classification of "obscene" and thus illegal for production and distribution has been judged on printed text-only stories starting with Dunlop v U.S. (1897), which upheld a conviction for mailing and delivery of a newspaper called the Chicago Dispatch, containing "obscene, lewd, lascivious, and indecent materials", which was later upheld in several cases. One of these was "A Book Named John Cleland's Memoirs of a Woman of Pleasure" v Attorney General of Com. of Massachusetts, "(1966)" wherein the book "Fanny Hill", written by John Cleland in 1760, was judged to be obscene in a proceeding that put the book itself on trial rather than its publisher. Another was Kaplan v California, (1973) whereby the court most famously determined that "Obscene material in book form is not entitled to any First Amendment protection merely because it has no pictorial content." In 2005, the U.S. Department of Justice formed the Obscenity Prosecution Task Force in a push to prosecute obscenity cases. Red Rose Stories, a site dedicated to text-only fantasy stories, became one of many sites targeted by the FBI for shutdown. The government alleged that Red Rose Stories contained depictions of child rape. The publisher pleaded guilty. Extreme pornographer Max Hardcore served 30 months of a 46-month prison sentence for obscenity. Many U.S. states have had bans on the sale of sex toys, regulating them as obscene devices. Some states have seen their sex toy bans ruled unconstitutional in the courts. That ruling leaves only Mississippi, Alabama, and Virginia with current bans on the sale of obscene devices. Literature (non-fiction) communicating contraceptive information was prohibited by several states. The last such prohibition, in Connecticut, was overturned judicially in 1965. --- Send in a voice message: https://anchor.fm/law-school/message Support this podcast: https://anchor.fm/law-school/support

With Antonio Cannata, King's College London, London - UK, Mateusz Sokolski, Wrocław Medical University, Wrocław - Poland, Otilia Țica, Emergency County Hospital of Oradea, Oradea - Romania, Finn Gustafsson, University of Copenhagen - Danemark, John Cleland, Imperial College of London - UK,  Theresa McDonagh, King's College London - UK, Gianluigi Savarese, Karolinska Institute - Sweden, Carolyn Sp Lam, National Heart Centre Singapore - Singapore & Marco Metra, University and Civil Hospital of Brescia, Brescia - Italy This podcast will discuss the insights and highlights shared by key-leaders in heart failure during the annual meeting: Heart Failure Congress, held in Madrid, Spain. Prof. Gustafson offers an overview on advanced heart failure therapies and the role of MCS (mechanical circulatory support). Prof Cleland debates when should we attempt revascularisation in  heart failure patients. Prof McDonagh shares the updates and changes in the implementation of the HF guidelines in the last year, since their release. Prof Savarese highlights the best scientific statement of this year, the universal definition of Heart Failure. Prof Lam provides key message and trials in HF and also underlines the sex-differences in these patients. Prof Metra discusses the pillars and future perspectives of HF and the importance of education. 

In this episode I talk about John Cleland's Fanny Hill or a Memoirs of a Woman of Pleasure. It's the first work in English to be censured for causing offence - perhaps not surprising since it's also the first pornographic novel written in English. The version of the text is that edited by Peter Wagner and first published by Penguin in 1985 - it's based on the original two-volume novel (1748-9), not the expurgated version (broken up into 11 letters, instead of the original 2) or any of the various illustrated versions that began appearing in the 1760s. Content Notes: This episode includes discussions of sex (between women, between men and women - including group sex, and between men), flagellation, defloration, non-consensual sex, prostitution, abortion, miscarriage, women's and children's bodily autonomy, incest, and Americans and guns. It also includes occasional use of four-letter words that some might find objectionable.

Host: Javed Butler, MD, MBA, MPH Guest: John Cleland, MD Guest: Fraser Graham, MD Iron deficiency is one of the most frequent comorbidities in patients with heart failure and is estimated to present in up to 50 percent of patients. So what's the criteria for iron deficiency, and how is it currently defined in cardiology? To discuss this, Dr. Javed Butler is joined by Drs. John Cleland and Fraser Graham from the Institute of Health and Wellbeing at the University of Glasgow.

 Lisa and Elisabeth Wang discuss The Four Winds written by Kirstin Hannah. This is a book that highlights the Dust Bowl and The Great Depression.  Elisabeth is a former English teacher and is currently in healthcare communications. She has written the bookish blog Lit & Leisure since 2009. You can also find her on Twitter or Instagram. The Washington Post suggests that perhaps if Kristin Hannah had more time to hone her skills and a little tougher editing, she could produce something excellent.  The New York Times writes that this will resonate with people now.  Books discussed:  Memoirs of a Woman of Pleasure by John Cleland and Richard Terry The Grapes of Wrath by John Steinbeck  East of Eden by John Steinbeck Butcher's Crossing by John Williams Stoner by John Williams and Elisabeth wrote this review about the book.  Twentymile by C. Matthew Smith The Remains of the Day by Kazuo IshiguroMy Sister the Serial Killer by Oyinkan BraithwaiteYou by Caroline Kepnes Yinka, Where is Your Huzband? by Lizzie Damilola BlackburnFor more information, find Lisa on Instagram, Twitter, Facebook and her website.  *The book titles mentioned include affiliate links. You can support the podcast by purchasing a book with the links because the podcast receives

Sharon Glynn speaks to Elizabeth Rimmer and John Cleland about the 'Life in the Law' report from LawCare, and how firms can better address the risks identified. Speakers: Sharon Glynn, Senior Development Underwriter, Solicitor and Large Law Firm Lead at Travelers. Elizabeth Rimmer, CEO of LawCare. John Cleland, Managing Partner at Pinsent Masons.

Django Nudo and the Smut Peddler celebrate the first #CultpixIRL cinema screening this past week at Bio Aspen, the groovy new retro cinema in Stockholm's new hipster district.  It was a double bill of "Anita - Swedish Nymphet" (1973) and "Kyrkoherden / The Lustful Vicar" (1970), both beautifully restored by the Swedish Film Institute. Guest of honour was Christina 'Anita' Lindberg herself and the authors of the book 'Frigjorda Tider' ('Liberated Times'), who talked about the period when these films were released, a time when "porn became culture and culture became porn."Sticking with the theme of culture and porn, DN and SP discuss the Cultpix Theme Week of Literally Erotic Women. Adapting classics of literature for provided good plots, a veneer of highbrow credibility and - best of all - they were out of copyright and the authors were too dead to complain about having their works adapted with lots of boobs, bums and other bits. Chief amongst these literary smut auteurs was Mac Ahlberg, who as Bert Torn, directed six literary adaptations that can be streamed on Cultpix now, including John Cleland's "Fanny Hill" (1968) and "Jorden runt med Fanny Hill / Around the World With Fanny Hill" (1974); Anonymous' "Flossie" (1974); Marqis de Sade's "Justine & Juliette" (1975); Daniel Defoe's Moll Flanders adaptation "Molly" (1977, aka "Sex in Sweden") and Guy de Maupassant's "Bel Ami" (1977).We discuss the stars who appeared in many of these, including the lovely Maria Forså (who apparently didn't fake it), Harry Reems and how he ended up in Sweden, the on-stage sex real life couple Jack and Kim Frank, plus the director Torgny Wickman, who insisted " on painting every clit a little pinker immediately before each take.'"There is also the early US nudie cutie "Kipling's Women" (1961), which was said to be based on "A Picturization of Rudyard Kipling's Immortal Poem---The Ladies," with the priceless tagline 'They Wear Only the Wind!'. And to prevent projectionists from cutting out the nudie bits of the 35mm prints, you could send of for free photos of the six lovely ladies in questions. Finally there is also the Austro-Hungarian turn-of-the-century smut classic Josephine Mutzenbacher, with two of the dozen adaptations available on Cultpix: "Naughty Knickers/Josefine Mutzenbacher" (1970) and "Don't Get Your Knickers in a Twist/Josefine Mutzenbacher II - Meine 365 Liebhaber" (1971). Many of these films are available too in multiple English, French, German and Swedish dub. So you can not only refine your cultural credentials, but also your linguistic one, by watching these films. Just like you used to read Playboy for the articles. 

   At 7pm on the evening of November 30,1948, John Lyon and his wife were walking along Somerton Beach, just south of Adelaide, South Australia, Australia. They noticed a well dressed man lying on the beach with his head propped up against the sea wall. The man was lying with his legs outstretched and his feet crossed. As the couple passed, they saw him raise his right arm and then it fell to the sand. John said it looked like a "drunken attempt to smoke a cigarette". A half hour later they were walking back the same way and noticed the same man was still there. There he was in his nice suit and polished shoes, an odd way to dress for lounging on the beach. He was still with his left arm laid out on the beach. The couple figured he was asleep, maybe passed out drunk. There were mosquitos buzzing all around his face. John commented to his wife "he must be dead to the world".          The next morning John Lyons would discover how right he was. As he was returning from a morning swim, John noticed a cluster of people gathered around the area where he had seen the drunk man the day before. As he approached the group he saw a man slumped over in much the same position as the man from yesterday. The body was lying there, legs out, feet crossed, cigarette half smoked lying on his collar, but this man was not drunk, he was dead. This was the man John and his wife saw the day before, this was the Somerton Man!    This case endures to this day as one of the greatest mysteries of Australia. No one is sure who the man is, why he ended up dead on the beach, or even how he died. Dr. John Barkley Bennett put the time of death at no earlier than 2 a.m., noted the likely cause of death as heart failure, and added that he suspected poisoning. The contents of the man's pockets were spread out on a table: tickets from Adelaide to the beach, a pack of chewing gum, some matches, two combs and a pack of Army Club cigarettes containing seven cigarettes of another, more expensive brand called Kensitas. There was no wallet and no cash, and no ID. None of the man's clothes had any name tags—indeed, in all but one case the maker's label had been carefully snipped away. One trouser pocket had been neatly repaired with an unusual variety of orange thread. A day later a full autopsy was carried out and revealed some more strange things. It revealed that the corpse's pupils were “smaller” than normal and “unusual,” that a dribble of saliva had run down the side of the man's mouth as he lay, and that “he was probably unable to swallow it.” His spleen, meanwhile, “was strikingly large and firm, about three times normal size,” and the liver was distended with congested blood. In his stomach they found his last meal and more blood. He had eaten a pasty, a folded pastry with a savoury filling, typically of seasoned meat and vegetables. The blood in the stomach also suggested poisoning but there was no evidence that the food was the cause of any poisoning. The poisoning theory seemed to concur with the strange behavior the man exhibited on the beach, instead of drunken behavior it could have been the behavior of a man who had been suffering the effects of poisoning. Now, while this theory made sense given the evidence, repeated tests on both his blood and organs by an expert chemist failed to reveal the faintest trace of a poison. “I was astounded that he found nothing,” Dwyer admitted at the inquest. In fact, no cause of death was found. Among all this weirdness, other odd things were noticed. The dead man's calf muscles were high and very well developed; although in his late 40s, he had the legs of an athlete. His toes, meanwhile, were oddly wedge-shaped. Testimony given by one experts went as follows:          I have not seen the tendency of calf muscle so pronounced as in this case…. His feet were rather striking, suggesting—this is my own assumption—that he had been in the habit of wearing high-heeled and pointed shoes.   Another expert had suggested that given these irregularities that maybe the man was actually a ballet dancer.    Putting all this together made… Well… Zero sense. The coroner was informed by an eminent professor that the only practical solution was that a very rare poison had been used—one that “decomposed very early after death,” leaving no trace. The only poisons capable of this were so dangerous and deadly that the professor would not say their names aloud in open court. (My mind goes to Ricin, a highly potent toxin produced in the seeds of the castor oil plant.) Instead, he passed the coroner a scrap of paper on which he had written the names of two possible candidates: digitalis and strophanthin. The professor suspected the latter. Strophanthin is a rare glycoside derived from the seeds of some African plants. Historically, it was used by a little-known Somali tribe to poison arrows.    At this point everyone was thoroughly and extremely confused. They took a full set of fingerprints and sent them all over Australia and then around the work to try and figure out who this guy was. There were no matches anywhere. They started bringing people with missing relatives into the mortuary to see if anyone recognized the man, no one did.    By January 11, the South Australia police had investigated and dismissed pretty much every lead they had. The investigation was now widened in an attempt to locate any abandoned personal possessions, perhaps left luggage, that might suggest that the dead man had come from out of state. This meant checking every hotel, dry cleaner, lost property office and railway station for miles around. But it did produce results. On the 12th, detectives sent to the main railway station in Adelaide were shown a brown suitcase that had been deposited in the cloakroom there on November 30. The staff could remember nothing about the owner, and the case's contents were not much more revealing. The case did contain a reel of orange thread identical to that used to repair the dead man's trousers, but painstaking care had been applied to remove practically every trace of the owner's identity. The case bore no stickers or markings, and get this, a label had been torn off from one side. The tags were missing from all but three items of the clothing inside; these bore the name “Kean” or “T. Keane,” but it proved impossible to trace anyone of that name, and the police concluded–an Adelaide newspaper reported–that someone “had purposely left them on, knowing that the dead man's name was not ‘Kean' or ‘Keane.' ” So, a subterfuge! Spy games! (I just love that word)   The police had brought in another expert, John Cleland, emeritus professor of pathology at the University of Adelaide, to re-examine the corpse and the dead man's possessions. In April, four months after the discovery of the body, Cleland's search produced a final piece of evidence—one that would prove to be the most baffling of all. Cleland discovered a small pocket sewn into the waistband of the dead man's trousers. Previous examiners had missed it, and several accounts of the case have referred to it as a “secret pocket,” but it seems to have been intended to hold a pocket watch. Inside, tightly rolled, was a minute scrap of paper, which, opened up, proved to contain two words, typeset in an elaborate printed script. The phrase read “Tamám Shud.”    Frank Kennedy, the police reporter for the Adelaide Advertiser, recognized the words as Persian, and telephoned the police to suggest they obtain a copy of a book of poetry—the Ruba'iyat of Omar Khayyam. This work, written in the twelfth century, had become popular in Australia during the war years in a much-loved translation by Edward FitzGerald. It existed in numerous editions, but the usual intricate police enquiries to libraries, publishers and bookshops failed to find one that matched the fancy type. At least it was possible, however, to say that the words “Tamám shud” (or “Taman shud,” as several newspapers misprinted it—a mistake perpetuated ever since) did come from Khayyam's romantic reflections on life and mortality. They were, in fact, the last words in most English translations— not surprisingly, because the phrase means “It is ended.” Weeeeird!   Taken at face value, this new clue suggested that the death might be a case of suicide; in fact, the South Australia police never did turn their “missing person” enquiries into a full-blown murder investigation. But the discovery took them no closer to identifying the dead man, and in the meantime his body had begun to decompose. Arrangements were made for a burial, but—being aware that they were disposing of one of the few pieces of evidence they had—the police first had the corpse embalmed, and a cast taken of the head and upper torso. After that, the body  was buried, sealed under concrete in a plot of dry ground specifically chosen in case it became necessary to exhume it. Oddly enough, As late as 1978, flowers would be found at odd intervals on the grave, but no one could ascertain who had left them there, or why.    In July, a full eight months after the investigation had begun, the search for the right Rubaiyat produced results. On the 23rd, a Glenelg man walked into the Detective Office in Adelaide with a copy of the book and a strange story. Early the previous December, just after the discovery of the unknown body, he had gone for a drive with his brother-in-law in a car he kept parked a few hundred yards from Somerton Beach. The brother-in-law had found a copy of the Rubaiyat lying on the floor by the rear seats. Each man had silently assumed it belonged to the other, and the book had sat in the glove compartment ever since. Alerted by a newspaper article about the search, the two men had gone back to take a closer look. They found that part of the final page had been torn out, together with Khayyam's final words. They went to the police.   Detective Sergeant Lionel Leane took a close look at the book. Almost at once he found a telephone number penciled on the rear cover; using a magnifying glass, he dimly made out the faint impression of some other letters, written in capitals underneath. Finally they had a solid clue!   So where did the clue lead them? Well the phone number was unlisted. But have no fear… They traced the number to a nurse who lived near Somerton Beach. The nurse has never been publicly identified. She is only known by the nickname Jestyn. She revealed to investigators that she had indeed given that book to a friend of hers, a man she knew in the war. She also gave them a name, Alfred Boxall.   Boom! Mystery solved!!! Right? Well maybe not so much. Detectives felt they had figured out the identity of the dead man. Except for the fact that when they tracked down Alfred Boxall in new south wales… He was still alive. Oh and also, the copy of the book he received from the nurse… He still had it and it was still intact. The gentle probing that the nurse received did yield some intriguing bits of information though; interviewed again, she recalled that some time the previous year—she could not be certain of the date—she had come home to be told by neighbors that an unknown man had called and asked for her. And, confronted with the cast of the dead man's face, Jestyn seemed “completely taken aback, to the point of giving the appearance she was about to faint,” Leane said. She seemed to recognize the man, yet firmly denied that he was anyone she knew.    That left the faint impression Sergeant Leane had noticed in the Glenelg Rubaiyat. Examined under ultraviolet light, five lines of jumbled letters could be seen, the second of which had been crossed out. The first three were separated from the last two by a pair of straight lines with an ‘x' written over them. It seemed that they were some sort of code. They sent the message to Naval Intelligence, home to the finest cipher experts in Australia, and allowed the message to be published in the press. This produced a frenzy of amateur codebreaking, almost all of it worthless, and a message from the Navy concluding that the code appeared unbreakable:             “From the manner in which the lines have been represented as being set out in the original, it is evident that the end of each line indicates a break in sense.   There is an insufficient number of letters for definite conclusions to be based on analysis, but the indications together with the acceptance of the above breaks in sense indicate, in so far as can be seen, that the letters do not constitute any kind of simple cipher or code.   The frequency of the occurrence of letters, whilst inconclusive, corresponds more favourably with the table of frequencies of initial letters of words in English than with any other table; accordingly a reasonable explanation would be that the lines are the initial letters of words of a verse of poetry or such like.”   The Australian police never cracked the code or identified the unknown man. The nurse, Jestyn died in 2007, so there's no possibility of ever getting her to reveal why she reacted the way she did when seeing the cast of the man. And when the South Australia coroner published the final results of his investigation in 1958, his report concluded with the admission:   I am unable to say who the deceased was… I am unable to say how he died or what was the cause of death.   And that's where the case sits   And that's it… Thank you guys and good night.   Oh wait… You want more? Fine.   The information on the initial case and investigation came from a great article on smithsonianmag.com   There… Still not enough…ok ok   So what about this nurse then. Turns out her actual name is Jessica Thompson and she passed in 2007 as stated earlier. Police had always felt she knew more than she was letting on. Her daughter would later say in an interview that she thought her mother knew the dead man. The reason her message was not released earlier is because she requested a pseudonym as she felt her connection to this case would be embarrassing. Why? Interesting. Some think that her real name is important because it may hold the key to deciphering the code. As stated earlier, her reaction to seeing the cast of the man led many people to think that she definitely knew the man. In a video we found the man who made the bust describes how when Jessica was brought in to see the bust she saw the likeness when a sheet was removed from it and immediately looked down and would not look at the bust again for the rest of the interview. It was during that interview that she gave them the information of Alfred Boxall. So the question remains with Jessica… Did she know the man? If she did know the man, why was she so informed to distance herself from this case? Was she involved in some way?   As far as the man himself, there are many theories floating around. One of the most prevailing theories is that he was a spy! We got us some James bond shit going down! Or maybe not. Others say he was involved in the black market as evidence but the clipped labels on his clothing. So he was dealing in babies and knock off clothing on the black market!!! Maybe not.  Well let's look into these theories and see what you guys think.    One man who thinks there is a spy connection is Gordon Cramer, a former British detective with links to former intelligence officers. He says parts of the code match with Morse code letters found in the World War II Radio Operators Manual. He believed micro writing hidden within the letters of the five lines of code appeared to refer to the de Havilland Venom — a British post-war jet, still on the drawing board at the time.   He also saw the Somerton Man's death coinciding with the start of the Cold War and, according to Mr Cramer, the visit to Adelaide of high-ranking British officials and weapons trials at Woomera — the later site of nuclear testing. So this guy thinks that's a link to show he may have been some sort of cold war spy. Other things that people say pointing to him being a spy include the family of our nurse friend telling 60 minutes Jestyn, aka Jessica Thomson may have been a Russian spy! And even crazier… That she may have had a son with the Somerton Man! This theory is further backed by another article we found. Derek Abbott, a professor of biomedical engineering at the University of Adelaide has spent over a decade studying the case.                “What makes this kind of go viral is, I think, just all the strange things. It kind of just gives you that creepy shiver down your spine.”    DNA, Abbott said, is a key to solving the mystery. “I'm not so interested in how he died, but giving him his name back is the most important thing.”   Abbott also noticed that the man also had two distinctive features: canines next to middle teeth and ears with large upper hollows. After examining the mysterious letters of the code in the late 2000s, Dr. Abbott said, “I kind of fell down the rabbit hole.” In 2009 he tried to track down Mrs. Thomson (our nurse friend) for an interview but found that she had died two years earlier. She had a son who had been a DUN DUN DUNNNN professional ballet dancer, Dr. Abbott learned, and photos showed he had distinctive teeth and ears similar to the Somerton man's. Oh shit son! Abbott decided to then track down this man but unfortunately he had died mere months before Abbott made his discovery. COINCIDENCE?? He found out that Thomson's son had a daughter of his own… So guess what… He tracked her down. And guess what… SHE was dead… Actually no that's not true she's still alive. The woman's name was Rachel Egan. Ms. Egan had never heard of the Somerton man, but she agreed to help Dr. Abbott in his effort to name the man who might be her grandfather. Dr. Abbott laid out that scenario: “The Somerton man had Jessica Thomson's number. He was found dead a five minutes' walk from her house. Rachel's dad was only 1 year old at the time, with no father. So you kind of put two and two together — but until it's absolutely confirmed, you never know.”   And Dr. Abbott acknowledged that, if usable DNA was obtained from the exhumed remains, it might in fact show his wife had no link to the Somerton man. “All I can say is there's lots of twists and turns in this case, and every turn is pretty weird,” he said.    Want another weird twist? Abbott and Egan fell in love and were married in 2010. And yes that part is true.    So, while he himself doesn't necessarily back the spy theory, his life of work could lend credence to said theory.    Several years ago, Ms. Egan had her DNA analyzed, and links were found to people in the United States (including relatives of some guy named Thomas Jefferson… yes, that Thomas Jefferson). More recently, links were also found to the grandparents of the man that Jessica Thomson eventually married. “So my head is spinning,” Dr. Abbott said. “Does that prove she's not connected now to the Somerton man? Or does that prove that somehow the Somerton man is related to her assumed grandfather? It's getting all complicated, so complicated that I'm just going to shut up now and let the DNA from the Somerton man speak for itself.”   Another strange connection that could lend itself to a spot connection is the remarkable similarities to the Mystery of the Isdal woman. On November 29, 1970, while hiking Isdalen (Ice Valley) near Bergen, Norway, a father and his two daughters witnessed a horrifying sight. Wedged between the rocks of the hiking trail, they discover a badly burnt female body. The labels of her clothes had been cut off and any distinctive marks had been removed as if to make her completely unrecognizable. The front side of her body had been severely burnt and she was found in a boxer's position, fists clenched. When you look into this case there are many similarities to the Somerton Man that we may just go ahead and cover in a bonus!   Again, Thomson's own daughter believed the Somerton Man to be a spy and that her own mother may have also been a spy. She said her mother taught English to migrants and spoke fluent Russian. Jessica had once told her daughter that “someone higher than the police force” also knew the identity of the mysterious man.   Another theory is that the Somerton Man was involved in illegal activities involving the black market that sprung up after WWII. People point to the missing labels on the clothes as pointing toward that possibility. Abbott who we discussed earlier had said that this seems a more likely route than the spy route. If he was involved in some sort of black market goings on or something similar, it would definitely explain the urge for someone to go to many lengths to keep his identity a secret. But what would the rest of the clues mean? Was the page or of the book meant to send a message to someone else? Some think the code found may have had something to do with black market shipments or deliveries, or possibly locations. Without solid evidence though this is pretty much all just speculation.  Many people are also subscribing to the theory that this was just a case of a jilted lover. They believe that the Somerton Man and the nurse were lovers and that they had a child together. After this some people think that Thomson rejected the Somerton Man for some reason and it led to the man taking his own life. This theory seems most plausible but at the same time, why has no one been able to figure out who this man was. It also makes sense in the line of Thomson being embarrassed by being involved in the case and her unwillingness to discuss it with police as she was dating another man at the time of the death who would eventually become her husband.    If you really want to get crazy with the cheese whiz so to speak, there are small groups of people that really are looking at the fringe theories. If you look into the far corners of reddit and other similar sites you'll find the usual theories of time travel and extraterrestrial origins. Those folks are definitely in the small minority but they are out there and most likely started by Mr. Moody.    Ok so where does all the craziness leave us? Well… We don't know. The Somerton man's body was exhumed earlier this year and we haven't been able to find any updates on any sort of DNA analysis, because as we know, these things tend to take some time. In articles as recent as July of this year they are still waiting on results. Part of the problem is that getting quality DNA samples from that old and degraded of a body can sometimes be difficult. So, while there are many theories on who the man was and the circumstances around his death no one knows for sure who he was and what happened. The one person who seemed to have at least some sort of knowledge of the man passed away without ever revealing her secrets. The other difficult thing is that every time a question seems to be answered it only opens up even more questions. Is the code really a code? Was the man a spy? Was the nurse a spy? Was anyone a spy? Was chainsaw involved? Where was he in 1948? As the old tootsie pop commercial used to say… the world may never know!  Best horror movies of 1948   https://www.pickthemovie.com/best-horror-movies-of-1948

How can we create classrooms where students WANT to learn? Episode one of Real Learning features a conversation with John Cleland where John shares powerful teaching techniques he uses to get his students to buy-in and take ownership of their learning. There is an art to teaching in a way that makes students feel eager to learn. Teachers who can connect with and lead their students to be curious, motivated learners have the power to change the tenure course of kids' lives. This is not about memorization and regurgitation. We are talking about sparking interest by making learning relatable. We are talking about cultivating classrooms where students are enthusiastic about thinking for themselves, asking great questions, and considering multiple perspectives. Empathetic classrooms where students are readily making connections between their lives and what they are learning in school. Our goal with this podcast is to share how some of the greatest educators we know get students engaged and allow for real learning to happen. Thank you for being here, and we hope you enjoy.

Learn More about Renewwest: https://www.renewwest.com/Learn More about Aclymate: https://aclymate.com/

John Cleland comes from an era when racing drivers were racing drivers, and touring cars were touring cars. That's what you'd hear if you asked a nineties super touring fan about the BTCC. Behind the on-track rivalries and the glamorous budgets, however were a group of superstar drivers who could barely have imagined the international stardom they'd enjoy, when they climbed behind the wheel of the racing versions of a selection of humble 'rep-mobiles'. Every super touring driver will tell you that the bubble had to burst at some point, shortly before they tell you it was one heck of a ride! In this episode of the Spinning Wheels podcast Guy and Paul go behind the visor of one of the world's best loved racing drivers who, you'll be pleased to know is every bit the character he was in the spotlight of his career.

James McCabe continues his discussion with Tony Whitlock. In Part 2, James talks about working in Supercars at Brad Jones Racing, with drivers like John Cleland, and Brad Jones. 00 Motorsport post Craig Lowndes and some of the reasons that smaller teams like Britek were setup to fail by the management of the category.

James McCabe continues his discussion with Tony Whitlock. In Part 2, James talks about working in Supercars at Brad Jones Racing, with drivers like John Cleland, and Brad Jones. 00 Motorsport post Craig Lowndes and some of the reasons that smaller teams like Britek were setup to fail by the management of the category.

James McCabe continues his discussion with Tony Whitlock. In Part 2, James talks about working in Supercars at Brad Jones Racing, with drivers like John Cleland, and Brad Jones. 00 Motorsport post Craig Lowndes and some of the reasons that smaller teams like Britek were setup to fail by the management of the category.

„Welche Wogen des Glücks. Welch selige Verschmelzung. Welch Todesqualen unserer Lust!“ Das Buch gilt heute als Klassiker der erotischen Weltliteratur.

Mike Nicholsons career has been spent at the top flight of British motorsport. He starred as a co driver during the halcyon days of the British Open Rally Championship alongside legendary names such as Tony Pond and Russell Brookes, and taking the title with in 1984 with Jimmy McRae. A career-long association with Vauxhall then saw the Derbyshire man take the helm of the Griffin's race programme, fielding drivers such as John Cleland, James Thompson and Jason Platoin the British Touring Car Championship during the revered Super Touring heyday. Guy and Paul go behind the pace notes and the deals to discover the story of one of the sport's great characters in the latest episode of Spinning Wheels.

Dr. Hayes interviews Dr. Lawrence Baker on his early involvement with SWOG ANNOUNCER: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. DANIEL HAYES: Welcome to JCO's Cancer Stories-- The Art of Oncology, brought to you by the ASCO Podcast Network, a collection of nine programs covering a range of educational and scientific content and offering enriching insight into the world of cancer care. You can find all of the shows, including this one, at podcast.asco.org. Today, my guest on the podcast is Dr. Laurence H. "Barry" Baker. Dr. Baker has a long and distinguished career in oncology. It dates back to the early 1970s, when he was intimately involved in new drug development, including doxirubicin or adriamycin, as we know it. He's also led early studies in preoperative chemotherapy in anal cancers. He was instrumental in advances in sarcoma research, and he led the Southwest Oncology Group-- now designated SWOG-- for eight years in the last decade. Dr. Baker was raised in Brooklyn, and since this interview is taking place just a week after the sad loss of Supreme Court Justice Ruth Bader Ginsburg, Dr. Baker informed me that he and his wife Maxine were married in 1964 in the Midwood Jewish Center, Justice Ginsburg's home synagogue. He received his undergraduate degree from the Brooklyn College at the University of New York, and then he graduated from Des Moines University of Osteopathic Medicine in Iowa. He completed a residency in internal medicine at Flint Osteopathic Hospital in Flint, Michigan, and then he has a curious two-year break in his curriculum vitae during which he was on active duty in Vietnam. Upon discharge from the Army, he returned to Michigan, and he served a three year fellowship at Wayne State University, where he stayed on faculty from 1972 to 1994, serving at various times as the chief of the Division of Hematology and Oncology, the chair of the Department of Medicine, and director of the Cancer Center. In 1994, he moved west about 30 miles to Ann Arbor, where he served as the director for the Clinical Research and Translational and Clinical Research Program for the UM Comprehensive Cancer Center, now called the Rogel Cancer Center. And he was also the associate chief of the Division of Hematology and Oncology and currently is the Laurence H. Baker Collegiate Professor in developmental therapeutics. Dr. Baker has authored hundreds of peer-reviewed papers, and like so many of our guests on this program, he has a list of honors that are just, frankly, too long to recite, except two that I want to highlight. He received the ASCO Distinguished Service Award for Scientific Leadership in 2007, and he was named an ASCO Statesman, now designated as a fellow of ASCO in 2010, for his many services to our society. Dr. Baker, welcome to our program. LAURENCE H. BAKER: Thank you. Nice to be here. DANIEL HAYES: Well, it's really great to have you. A lot of questions, but I want to start out, I just can't help but ask you, to be trite, how does a nice boy from Brooklyn end up in the Midwest for the rest of his life? Can you give us some stories about how you got there? LAURENCE H. BAKER: I graduated high school at 15 and went into what some know-- but not everyone knows-- was a very competitive college. Brooklyn College accepted-- was a free school. The grades used in the New York City school system were numerical. They weren't letters. And you had to have a 90 average on high school and certain scores on the state, New York State examinations to get in. And that was it. It didn't matter where your parents went to school. It didn't matter if you had money. And so it was a school largely of relatively low-income families. But that's the one who took me, and I guess they accepted me at 15. To not make this into a long story, but to drag it out a little bit, I was fascinated that I was 15 and I could date 18-year-old girls, and they didn't know it. So that's how I spent the first two years of college. And my grades showed that that was my focus of attention. I did pretty well on the MCAT examination. I would not have gotten into a medical school in this country, and I didn't speak a language that would be sufficient for me to go to Europe, for example, to school. So osteopathy he was where I went. I went to Iowa, but their admitting question to me is, do you have $2,000 a year tuition? To which, of course, I lied. And that's how I ended up being a DO, and that's how I came to the Midwest. And I actually got to like the-- I didn't know anybody from Iowa, as you make reference to my Brooklyn background, but I actually came to really appreciate the Iowa people, and particularly the community people that I came to know. At the time there were-- the really good programs in residency in medicine were in Michigan. That's the direct answer to your question. That's how I came to Michigan. Just about then, just about could have gone to California and gotten an M.D. degree just by taking the licensure examination. And then, that closed. That opportunity closed. So a long story to your question. So I came to Detroit, into Flint, and then returned back to Detroit, and I've been in Michigan ever since. DANIEL HAYES: Now, that raises the second issue I talked about a minute ago. And that is, many of our guests were so-called Yellow Berets at the NIH in the late 1960s and really changed our practice. But you actually ended up in the Evacuation Hospital at Cu Chi in Vietnam. And I've heard horror stories about this. How did that happen? What did you do there? Enlighten me. LAURENCE H. BAKER: Well, there were good and bad things about being an osteopath. The American Osteopathic Association was always in conflict, was always trying to defend itself. And at the time that the Vietnam War was going on, the DOs were not eligible for military service as an officer. You could go in as an enlisted man, but not as an officer. But there was a great need for primary care physicians in Vietnam, and the understanding of the military physicians was that all DOs were primary care physicians. So a deal was struck between the AMA and the Department of Defense that led to the drafting of everyone in my medical school class. Every one of the men-- not women. Every one of the men was drafted. There was a universal draft. I then-- I was given a choice. I could volunteer for the Army or go to jail. Those were the choices. And I had, at the time, two little children with Maxine, and I was not-- you might guess-- not a big fan of the Vietnam War. The alternative was to go to Canada, and I wasn't secure enough to consider that I could actually practice medicine. It was uncertain. So I went in. When I got there, they asked me, did I have any interest in anesthesiology or radiology, because they were really short of those two. And of course, being who I am, I said, if you need a radiologist or an anesthesiologist, why don't you go draft one and let me go home? That didn't work, and so I became-- I was assigned to radiology. DANIEL HAYES: [LAUGHS] LAURENCE H. BAKER: They sent me to Fort Jackson, where-- no, that was actually a good experience then, because I learned a lot about imaging, and I still have interest in imaging, but I don't qualify anymore. This is before CAT scans and MRIs. This is IDPs and upper GIs, right? So anyhow, barium lower bowel examinations. So I was trained for six months, and I stayed on for another few months on staff there and then, lo and behold, was sent to Vietnam. I was sent for a year, but I volunteered to stay an extra month so that I could return without any further obligation to the military and begin my fellowship on July 1, which I had actually secured before I went to Vietnam. So that's the gory details of that. I was elevated to Major about, oh, a few months before I was discharged. And then, because they weren't nasty enough to me when I got home, into my fellowship, I then got a letter congratulating me on being in the active reserve. So I had to go two weeks every summer. That was my summer vacation during fellowship and beginning of faculty. And I had to go once a month for a weekend to play soldier with a bunch of guys who were lucky enough that they didn't have to go to Vietnam. And now we're even, I think. So it was an interesting experience, as I've shared some of it with you. It still is a painful experience in some ways. I was out the busy [INAUDIBLE]. DANIEL HAYES: If you don't mind, a quick story you've told me before about the child with leukemia. LAURENCE H. BAKER: Yes. So they made me a radiologist. I'm not a great-- it doesn't matter where you call me. I am who I am, and I'm really interested in patient care. And there were already five internists, and there was only so much gonorrhea that the troops could acquire. So I volunteered to open a pediatric clinic. And the Army thought that was a good thing for publicity. They did stories about it. Anyway, I opened the clinic for pediatrics. I knew nothing about pediatrics. I mean, the truth is, I had a month of rotation. My wife sent me my textbook. It was Nelson's Textbook of Pediatrics. Nothing I ever saw in Vietnam was ever in Nelson's Textbook. But I did what I could of trying to treat the children as best I could. And along came a young girl, eight years old, who had acute lymphacytic leukemia. I had a wonderful pathologist who was my hoochmate. "Hooch" is translated, there were eight guys who lived in a place. That was called a hooch. And he was a pathologist, and he made the diagnosis of ALL. I had my books from my mentor teaching me about chemotherapy. So even though I hadn't started the fellowship, I had some resources about chemotherapy. And now I had to find chemotherapy. Treated her with-- I started with steroids and penicillin, and then I went to find drugs. I was able to-- I won't tell all the details, but I was able to get drugs at an old French hospital in Saigon. And so I would visit that hospital pretending great interest in the pharmacy, but of course, I stole whatever drug I could steal when the pharmacy wasn't looking. And that included some alkylating agents, methotrexate, 6MP. And so I tell Jay [INAUDIBLE]-- to get to where you want to be, perhaps-- that I invented the bicycle therapy, which was every month, you changed the drug to try to avoid resistance. So that's what I did by necessity. [LAUGHS] And I actually-- there was a second child that I also treated. When I left, they were both in complete remission. And I think that that's what you're asking me. I was lucky that I didn't get shot or thrown in jail for many of these escapades. But I look back and think that at least I did somebody some good. So-- DANIEL HAYES: Kind of makes the current generation who complains about work hours look in a different light, I think. LAURENCE H. BAKER: Yeah, we worked every day. We worked seven days a week with-- there was no such thing as time off. This was the busiest American hospital, certainly in Vietnam, and some think the busiest hospital since the Atlanta train station in the Civil War. It was in Cu Chi, which was on the way to Cambodia, which is, of course, where the North Vietnamese troops would enter into South Vietnam. So it was a major, major place. It was about an hour, an hour and a half west of Saigon. DANIEL HAYES: Let's move on to the rest of your career. You come back, then, and trained at Wayne State, and at the time, [INAUDIBLE]-- and I can never pronounce his name. I'll have you do it. Dr. Venutius Vicevicius-- I always heard him Dr. V.-- who was, I think, a real character and really was one of the first chemotherapy pioneers. Can you tell us more about him? Because we've heard a lot about the folks on the East Coast and the folks in Texas, but not so much what was going on in the middle of the country at the time. LAURENCE H. BAKER: Yeah, Dr. V, or Dr. Vicevicius, who was Lithuanian, he has a story of his life that certainly makes me look like a slump. He was a guest of the Nazis, and then he was a guest of the Russians when Auschwitz was freed. So this was as a child. He grew up in a very educated and somewhat affluent family in Vilnius. And when he got out of these camps, he actually got to medical school in Frankfurt, Goethe Medical School in Frankfurt. He had major interest in biochemistry and, without speaking more than three words of English, chose to come to the United States. And he landed-- I don't really know why; I've heard so many different versions-- but he landed in Detroit and showed up at the Detroit Receiving Hospital-- this would be like LA County or Bellevue in New York, that sort of thing, knife and gun club-- not speaking any English but wanting to do training. And somebody was smart enough to accept him. And so he did his training. He also trained-- after medicine, he trained with Mike Brennan-- that's another name from the past who is a past president of ASCO, by the way, the second or third person, perhaps. Mike was present of the Michigan Cancer Foundation and was the card-carrying medical oncologist in the Detroit area. He trained Dr. V., and he trained another man named Bob Tally, who had a great deal of history to contribute to oncology. And then, V was recruited by Wayne to come there and started a program. He was an extraordinary person. English was the eighth language he learned, and he actually taught me how to write. I flunked college English. I had to take it twice. But he taught me how to write and, I think, made me a better writer. He certainly was an inspiration. His devotion to patients was extraordinary. His knowledge was extraordinary. And so he was a great, great teacher. And one of his major early contributions was the recognition that you could make the drug float-- they had four drugs or five drugs at this time-- but one of them was 5-fluorouracil, that was developed by Fred Ansfield in Minnesota. The drug was given for five days and then every other day until their mouth fell out or their white count got to zero. And maybe that's a little of an exaggeration, but not much. At any rate, he figured out if you gave the drug by continuous infusion-- because it had a rather short half-life-- you could avoid a great deal of the toxicity. And that's how infusion of fluorouracil got its start. He then went on to combine it with other drugs and with radiation, and that was the backbone of this anal canal achievement that you mentioned in the introduction. I had very little to do with it, but I was a cheerleader. It was a rectal surgeon who came to us at the time, and those familiar with that disease-- which we now know is a virus disease that could be prevented, but at that time, nobody had any of that-- the treatment was abdominal perineal resection, and it had to be among the most horrible things we did to people. And the surgeon came to us and said, listen, you guys always squirt those drugs in after they relapse, and I'm really tired of this. Maybe you could give those drugs first, OK? And that's how neoadjuvant chemotherapy got started. It wasn't our idea. It was a surgeon's idea. That story gets repeated again in orthopedics, but that's how it began in anal canal tumors. And so we gave 5FU infusion, and mitomycin, and radiation preoperatively. That almost always shrunk the tumor, by the way-- almost always significantly shrunk the tumor. The patient then once they went through that operation but was cured. And so you took a horrible disease and changed its natural history with that development. If it works once, you know, in oncology, then you try it a second and third time. And I had very shortly thereafter the opportunity to work with a wonderful Japanese pediatric oncologist in Houston, Watsu Tao. He was looking for a partner because he was tired of seeing osteosarcoma patients die. Cure rate at the time was around 20%, 30%, and the surgery that was done for osteosarcoma was amputation, usually of the lower extremities. So 2/3 of osteosarcomas occur around the knee, and the orthopedics really dislike the idea of taking a child's leg off. Every teenager and child wants to be exactly like every other teenager and child, so you can imagine how disruptive it is to have a high amputation of your leg. It took about three months to make a prosthesis, and everyone knew that you didn't really have to do an amputation. You could just cut out the bad bone and replace it with a prosthetic device. But it took three months to make it, because they were handmade at the time. And so the idea came to several people-- Jim Holland was involved in this; Tom Frei was involved in this as well. Different cities were approaching it in this way. And we all ended up giving chemotherapy to these young people-- children, teenagers-- and then having the operation. And osteosarcoma went a cure rate of 20% to 30% to 70% or 80%. And they didn't lose their legs. DANIEL HAYES: I have two personal comments on this. One is you mentioned Dr. Brennan and the Michigan Cancer Foundation. Just for our listeners, Michigan Cancer Foundation is MCF. And if you've done any breast cancer work at all, you've worked with MCF-7 cells or MCF-10 cells [INAUDIBLE], which came from that organization. I think people have forgotten what MCF stands for, except for you and me. LAURENCE H. BAKER: That cell line that you talked about, MCF-7, that was developed by a man with, I think, a high school degree who just had a green thumb at that growing cells-- a wonderful man. And that came from a patient of ours. When I say "ours," I mean Dr. V. I was just the flunky, but it was his patient. And she had ascites from breast cancer. And we would tap ascites, in those days, with some frequency. And the cells for MCF-7 came out of that patient. That's its actual origins, and more papers have been written about MCF-7 than even you and I could count. DANIEL HAYES: Including by me. LAURENCE H. BAKER: I understand. No, it was incredibly useful. I mean, we learned about hormone receptors from this [INAUDIBLE]. DANIEL HAYES: Yep, that's [INAUDIBLE]. LAURENCE H. BAKER: It's was incredible. DANIEL HAYES: My other personal story related to your stories is, as a fellow at the then Sidney Farber Cancer Institute, Dr. Frei was my boss. And he, as you mentioned, was starting to work with Holland and others that had already worked with neoadjuvants. And he would cite your data all the time. Now, I didn't know Larry Baker for us from all the tea in China, but we heard a lot about the Wayne State experience when we were fellows. I don't know if that would have [INAUDIBLE] or not, but people definitely-- LAURENCE H. BAKER: No, I came to SWOG-- which is really why you wanted, I think, to talk to me-- in '70 or '71, I can't remember exactly. And Dr. V, it was an incredible experience. He took me with him. You ran into Tom Frei. They knew each other. And he said, Tom, I want you to meet my colleague, Larry Baker. I just had never been introduced like that. DANIEL HAYES: [LAUGHS] LAURENCE H. BAKER: And Tom was the friendliest person I think I've ever met in oncology. He had a wonderful smile. He clearly-- I was always paranoid that I'm a osteopath. Maybe I went on too long about that story. But when they tell you in school you're just as good as the MDs, you can quickly figure out if you were just as good, they wouldn't keep saying it, right? So that's socially accepted paranoia, and that's how I was brought up. So here is the wonderful, famous Tom Frei being nice to me! I was just amazed. DANIEL HAYES: He used to come to the lunch room in the Dana Farber two or three times a week and would just sit with us, and was constantly thinking of new stuff. This is not an interview with me, but someday, I'd like to tell the stories he told us. He was really just a fabulous man. I want to segway into your work with adriamycin, which is now, of course, also one of the workhorses of oncology. We've all used it. And I believe you were an author on either the first or one of the first phase II trials of adriamycin in Cancer in 1973. Is that an outgrowth of that introduction you just told us? LAURENCE H. BAKER: Yes. That study-- it's in Cancer, I think, not-- I don't think JCO existed. But that study didn't distinguish what the primary was. So it was a phase II study of cancer. And so there was, I don't know, 800 patients. I worked with Bob or Brian on that study. Bob was at Henry Ford, and there was a student of Bob Tally that I had mentioned, and I was the student of V. And the two of us were basically the schleppers for them. And so it had hundreds of patients in it. And in that study, we recognized that it worked in breast cancer, that it worked in lymphoma, and it worked in sarcoma-- and nothing worked in sarcoma. So that was the study. It's often quoted by Jim Dorshow because he said, we do everything that's disease-specific, but look what came out of one study that, by the way, accrued, as I say, 600 or 700 patients in 18 months. And this is before computers, so you can imagine how much work was done to evaluate the flow sheets. It was an incredible opportunity here to work. But it was an amazing paper, and it changed my life, of course. That's how [INAUDIBLE] and other things. DANIEL HAYES: So at the time, you recognized that this was not just another drug off the shelf, that it really was going to be a game-changer? LAURENCE H. BAKER: Absolutely, absolutely. You saw people getting better. And my experiences were mostly in breast cancer patients getting better, and some lymphoma patients that were refractory. First time I saw solid tumor patients dramatically improve. DANIEL HAYES: So I saw that your name is before another giant in the field who was a young Italian investigator who spent time in the United States named Johnny [INAUDIBLE]. LAURENCE H. BAKER: Yeah, that's how I first met him. I don't know that this story's been told. We were trying to make some level of peace with the Russians, and the Russians, of course, claimed that they discovered adriamycin. I don't know, but if you don't know this, I'll continue. DANIEL HAYES: Please go. LAURENCE H. BAKER: OK, but we all-- everyone knew, and certainly [INAUDIBLE] knew, this was an Italian drug, OK? "Adriamycin" is for the Adriatic Sea. As far as I know, you can't see the Adriatic Sea from Russia. But this was a time when our government wanted to be nice. They cared more about building a relationship with the Soviet Union than they did continuing a friendship with the Italians. Jim Holland was then sent to Moscow to negotiate this. That's where the name doxirubicin came from. In other words, we didn't know generic names, trade names. This didn't exist in the early '70s. So we called it adriamycin, which was not only the generic name, it was the trade name, right? Made by adria-- I think far Pharmitalia is the name of the company, right? And as a result of Jim Holland's diplomacy, it became doxirubicin as the generic name. It's a true story. DANIEL HAYES: Yeah. I know that "adria--" came from the Adriatic Sea, but I've not heard that's where "doxi-" came from. That's a good story. That segways into the next segment of your life that fascinates me, and this is your work in SWOG. When I moved here to the University of Michigan, you were on your way to becoming the chair of SWOG, which you did. And it occurred to me that University of Michigan wasn't even in Southwest Michigan, let alone the Southwest of the United States. Just reminisce a little bit about Dr. Coltman, who ran SWOG, the beginnings of SWOG, even before that, and where you see the [INAUDIBLE] groups now. LAURENCE H. BAKER: So Dr. V brought me to a SWOG meeting in San Antonio, Texas, as you said, in 1970 or '71. At the time, Tom Frei was running the group. J. Freireich was chairman of the Leukemia Committee. Chuck Coltman was chairman of the Lymphoma Committee. V specifically chose to work with this group because of those people. You're right, Michigan is not in the Southwest, obviously, and, there were other groups that wanted-- we had a large population of patients we treated, so there was actually some competition, if you will, for us to join other groups. V was adamant that we would be SWOG and that was it, for reasons that I told you. Tom Frei then was invited to go back to Boston. That's how you came to know him. And there was an election for a replacement. And J. Freireich was somebody that we clearly supported. There was no doubt that J. an absolutely brilliant man-- he still is-- and taught a lot of people, trained a lot of people, and taught us a great deal. But he had one flaw. He could not control his ability to saw inappropriate things. If you knew him, you loved him. If you didn't know him, you were like your reaction to the debate, OK? That's how he ground on people. I grew up with the respect for J., as I told you, as I was introduced to him, and he was always incredibly kind to me. Anyway, so we were actively supporting J. To be the replacement. There were some other people that did not want Freireich. So you had some people who didn't have the same feeling. And that's how Boris Hoogstraten became chairman. Boris Hoogstraten was a hematologist from the University of Kansas. And I remember-- and you'll be very proud of me, Dan-- one of my colleagues from Wayne wanted to do a study of this new drug called tamoxifen-- DANIEL HAYES: [LAUGHS] LAURENCE H. BAKER: --for breast cancer, OK? [LAUGHS] And Hoogstraten said, don't you get it, Baker? We're a chemotherapy group. What's with this hormone stuff? I don't have to tell another story, but that one is true. So SWOG didn't study tamoxifen for a long time. Any rate, Boris was an interesting man. I don't want to cut him short. But there came a time when it was clear that SWOG needed to go in a different direction. And we all thought that the right person for that was Chuck Colton. At the time, I have to tell you, there was two things relevant to this. There were lots of regional cooperative groups that don't exist anymore. I led a revolt-- that's what Colton said-- that included the University of Indiana-- Larry Einhorn was in Detroit plotting against Hoogstraten-- along with the University of Michigan. Al Labulio was in Detroit doing that. So you got the idea. So it was a group of institutions, if you want, that were geographically somehow related to the Great Lakes in some way. There were seven or eight of us. And we represented probably 40% of the [INAUDIBLE] of SWOG. And Coltman came to me and said, listen, stay with the group. Don't do this. Stay with the group. And I said, I can't stand this nonsense. I mean, we're not working anymore. We're just-- Anyway, he said, please stay. And he ended up becoming the chairman. And then he turned to me and he said, listen, Larry, I want you to be the deputy. I don't need a title. I don't want a title. He said, no, no, no, I don't care what you need or what you want. I need you right next to me, because if you led a revolt once, I don't want to see it happen again. DANIEL HAYES: [LAUGHS] LAURENCE H. BAKER: Absolutely true story. And so we abandoned the idea of a regional group. I still think that may have been a dynamite group, by the way. But we all stayed-- Indiana was not [INAUDIBLE] SWOG, so let me be clear. That was ECOG, I think. I think that's right. Anyway, so that's how I came to know Chuck, and I was his deputy for 25 years. I had the best job as deputy, because I had nothing to do. He just wanted me sitting there, and that's what we wanted. Then there was some push from the NCI that maybe to 25 years of being chair is a long time, and maybe there's a reason to move on. From that team the suggestion from Bob Livingston and John Crowley, that I was the natural person to do that. I really didn't want it, to be honest. I still maintain that. But there was a good deal of pressure exerted, both from within the group and from the NCI, for me to do that. So I became the chairman, I think, for a couple of terms. I made some changes in the group. I think as groups go on, institutions either get better or they get worse. I think that's true. And we made a number of different ways of appointing disease chairs and things like that, that the group did get better and started on a better path. But I really didn't want to continue it, and there was a time when I was not only running SWOG, but I was also running this sarcoma group called SARC. And it became overwhelming to me. I was working literally 80 hours a week there. So I gave up SARC first. That really-- University of Michigan was thrilled that I did that-- and stayed with SWOG another year or two. But I knew that I wasn't going to stay at that. And so after two terms, I thought I would set the precedent that, maybe, group chairs should have two terms and move on. Witshoski had two two terms. [LAUGHS] But anyway, being serious, I really think there should be a limited amount of time. There's so many talented people in our field that it's silly to think that one person has to stay in these jobs. And so that's-- I think I answered your question. I'm not sure my [INAUDIBLE]. DANIEL HAYES: I have to tell just a brief-- Nobel laureate Bruce Beutler was my intern when I was a resident at UT-Southwestern. After he won the prize, he came up here as a visiting professor, and we went to dinner. And I said, Bruce, I kind of lost track. I know you did an internship with us, but I never heard if you finished your clinical training. And he said, no, I went-- I loved the lab and went back into it. I never did go back and finish my training [INAUDIBLE]. And then he looked at me and said, but I think I worked down all right, don't you? LAURENCE H. BAKER: [LAUGHS] DANIEL HAYES: And in a similar manner, I would say, for all your humility that you've laid out, I think it worked out all right. SWOG is a powerhouse and has changed practice in so many ways. And part of that, a lot of that, was your doing. So we've actually run out of time. I had hoped, actually, to-- you've done too much in your lifetime, Larry. I was hoping to get into the sarcoma work, but we've run out of time. I think everybody who's listening to this who knows about the work you've done in sarcoma-- and lord knows there's plenty of work to do in sarcoma, so-- LAURENCE H. BAKER: Can I give you just one more anecdote, and you can cut it, and I'll try to be very [INAUDIBLE]? DANIEL HAYES: No, no. Please do, please do. LAURENCE H. BAKER: Remember I told you I became chair of the Sarcoma Committee of SWOG? The man I replaced was a man named Jeff Gottlieb. Jeff was a pediatric oncologist-- little did people know-- who was a student of J and Tom at the NCI. Jeff died in his mid-30s of cancer, by the way, but he was the most brilliant medical oncologist I ever met. He was the originator of combination chemotherapy that became popular in breast cancer, and he was involved in sarcomas in combinations as well. I was handpicked by Jeff to be his replacement, which was probably the nicest thing that ever happened to me. And during that period when Jeff died, I went to Houston to his funeral. And I can give you one-sentence description of J. Freireich going to speak at Jeff's funeral. He stood up, and he said, Jeff-- and he broke down and cried for minutes. And that was his talk. When anyone says something to me critical of J. Freireich, I remember that love he showed to his colleague. So that's worth [INAUDIBLE]. DANIEL HAYES: No, that's-- LAURENCE H. BAKER: Not many people were at that funeral. DANIEL HAYES: --very touching. He also gave Dr. Frei's eulogy in Boston, and he got through it, but just barely. It was very similar. These are the kinds of stories I'm hoping to capture in this series. Larry, I'd really like to thank you for taking time to be on. I'd also like to thank you for all you've done for the field, for me personally, frankly, with my time here in Michigan the last 20 years, and most importantly, for our patients who have benefited from all your contributions, your training of-- we could go on about all the people you've trained. So anyway, thanks a lot. We appreciate it. LAURENCE H. BAKER: Thank you. DANIEL HAYES: And have a nice day. LAURENCE H. BAKER: Thank you very much. I appreciate your kind words. DANIEL HAYES: Until next time, thank you for listening to this JCO's Cancer Stories-- The Art of Oncology podcast. If you enjoyed what you heard today, don't forget to give us a rating or review on Apple Podcasts, or wherever you listen. While you're there, be sure to subscribe so you never miss an episode. JCO's Cancer Stories-- The Art of Oncology podcast is just one ASCO's many podcasts. You can find all the shows at podcast.asco.org

On the Shelf for July 2018 The Lesbian Historic Motif Podcast - Episode 61 with Heather Rose Jones Your monthly update on what the Lesbian Historic Motif Project has been doing. In this episode we talk about: Recent and upcoming publications covered on the blogThe Zimmern Chronicle Brantôme's Lives of Fair and Gallant Ladies “From Huw Arwystli to Siôn Eirian” by MIhangel Morgan, queer Welsh literature Primary source material for the study of 17th century English women Emma Donoghue looks at the intersection of the motifs of hermaphrodite and lesbian in 17-18th century England Clorinda Donato considers John Cleland's translation of the life of Catherine VIzzani as a satirical attack on Mary Wortley Montagu Jacqueline Holler considers the trial confessions of a 16th c Mexican holy woman, heretic, and sexual outlaw Susan Lanser discusses the political implications of women's same-sex relationships in 17th century England Tim Hitchcock looks at homosexual subcultures in 18th century England Announcing this month's author guest, Justine Saracen New and forthcoming fictionJ B Marsden The Travels of Charlie (Sapphire Books) Kelly Wacker Holding Their Place (Bold Strokes Books) Rebecca Harwell Shadow of the Phoenix (Bold Strokes Books) Natalie Debrabandere Thyra's Promise (self-published) Claire O'Dell A Study in Honor (Harper Collins) Ask Sappho: Sheena asks, "Were there 'drag king' performances before the 20th century?"Rowson 2003 Gender Irregularity as Entertainment: Institutionalized Transvestism at the Caliphal Court in Medieval Baghdad Westphal-Wihl 1989 “The Ladies' Tournament: Marriage, Sex, and Honor in Thirteenth-Century Germany” Knighton 1995 Knighton's Chronicle 1337-1396 Mary Frith aka Moll Cutpurse Hannah Snell Straub, Kristina. 1991. “The Guilty Pleasures of Female Theatrical Cross-Dressing and the Autobiography of Charlotte Charke” Lesbian Historic Motif Podcast Episode 19d - Charlotte Cushman Sears, Clare. 2015. Arresting Dress: Cross-Dressing, Law, and Fascination in Nineteenth-Century San Francisco. A transcript of this podcast is available here. Links to the Lesbian Historic Motif Project Online Website: http://alpennia.com/lhmp Blog: http://alpennia.com/blog RSS: http://alpennia.com/blog/feed/ Twitter: @LesbianMotif Discord: Contact Heather for an invitation to the Alpennia/LHMP Discord server The Lesbian Historic Motif Project Patreon Links to Heather Online Website: http://alpennia.com Email: Heather Rose Jones Twitter: @heatherosejones Facebook: Heather Rose Jones (author page)

Dr Hayes interviews Dr. Lawrence Einhorn and patient, John Cleland, on the cure for testicular cancer.     The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Welcome to JCO's "Cancer Stories, The Art of Oncology," brought to you by the ASCO Podcast Network, a collection of nine programs, covering a range of educational and scientific content and offering enriching insight into the role of cancer care. You can find all of the shows, including this one, at podcast.asco.org. Welcome to the "Cancer Stories." I'm Dr. Daniel Hayes. I'm a medical oncologist and a translational researcher at the University of Michigan Rogel Cancer Center. And I've also been privileged to be the past president of ASCO. I'll be your host for a series of podcast interviews with the founders of our field, have been, and will continue to be over the next several months. In this series of podcasts, I'm hoping to bring the appreciation of the courage and the vision and the really scientific background among the leaders who founded our field of clinical cancer care over the last 70 years. I hope that by understanding the background of how we got to what we now consider normal in oncology. We can all work together towards a better future for our patients and their families during and after cancer treatment. Today, my guests our Dr. Larry Einhorn, who first demonstrated the cure of testicular cancer with cisplatin. And we have a special guest, Mr. John Cleland, who as far as I know was the first man to be cured of this cancer with cisplatin in the world. Dr. Einhorn is currently the Distinguished Professor of Medicine on the faculty of the section of hematology oncology at Indiana University School of Medicine. Mr. Cleland is now retired after a distinguished career as a high school teacher in track and field coach in Indiana. This interview is really particularly poignant for me. I knew John Cleland socially before I had ever heard of Larry Einhorn because our respective wives worked together while I was in med school as I began my clinical training. I then had the enormous privilege of being assigned to the oncology ward at the University Hospital for one of my rotations in internal medicine during my third year of medical school in 1977. And Dr. Einhorn was the attending. And frankly, for me, the rest is history. I had no chance. I had to become an oncologist. Dr. Einhorn received his undergraduate degree at Indiana University, went to medical school at the University of Iowa. He then returned to Indiana for his residency and fellowship. But he spent an oncology fellowship year at MD Anderson, Houston. After that you then returned back to IU in 1973 and has remained there ever since. He has won nearly every award and honor available in clinical research. And I'm not going to try to name them all, but most importantly, like me, as many people in this podcast series, he has served as president of ASCO, in his case, in the year 2000 and 2001. Dr. Einhorn and John, welcome to our program. Thank you. Thank you. Thank you. Dr. Einhorn, I'll start with you. Obviously, your greatest contribution is the cure for testicular cancer, which is pretty good. Can you kind of walk us through the history? How did you get involved with cisplatin? How did you derive the three drug regimen? What were the early obstacles? Especially with your returning back to Indiana. Can you kind of just walk us through that history? Certainly. So as you mentioned, I did a one-year fellowship in oncology at M.D. Anderson before returning to the faculty in 1973 and Indiana University. And in that time period, which was 46 years ago, the thought was that you might be able to cure adult leukemia like was cured with childhood leukemia from the wonderful studies from St. Jude's and that the studies that were ongoing in lymphomas and other hematological malignancies were very promising. But it was felt that you really don't want to do too much toxicity in a solid tumor, where you're getting a one log kill before you get progressive disease. And there was a clear pervasive atmosphere of pessimism of what can be done with solid tumors in general. So when I joined the faculty in 1973, I was the only oncologist. We had two hematologists that were there in our small faculty, which went from 2 to 3. And I wanted to be involved with both liquid tumors as well as solid tumors. But I wanted to be involved with solid tumors that were chemo sensitive. And even back in the early 1970s, testicular cancer was responsive to older drugs like actin or myosin-D and later with a two-drug combination of vinblastine plus bleomycin. And there were a small number of not just remissions but cures, and that was one of the few solid tumors that actually had a modest cure rate back at that time. And then the platinum story came around. And this is a podcast of itself with the wonderful work of a biophysicist at Michigan State, Dr. Barnett Rosenberg, who first discovered that platinum could be the first heavy metal ever to be looked at as antineoplastic agent. And when platinum entered first in human clinical trials in 1972 and 1973, it was [? selfed ?] at an NCI-sponsored phase I working group that I attended that this drug was producing minimal benefit and tremendous toxicity, especially horrendous nausea and vomiting. And the drug was pretty close to being discarded as a interesting novel mechanism of action, but not a drug that really had much of a future. But what changed the history of platinum and changed the history of testis cancer was the fact that among the phase I patients were treated with platinum, which included melanoma, lung cancer, colon cancer, breast cancer, the usual type of patients that enter phase I studies back in those older days were 11 patients that had testicular cancer who had failed actin or myosin D, failed vinblastine, plus bleomycin, and so they received single agent platinum. And when we, even today-- Actually, where were those studies done? That was done at Roswell Park actually, phase I study. And Roswell Park-- and this was an era, by the way, that there were only four NCI cancer centers in the United States, Roswell Park, M.D. Anderson, Memorial Sloan Kettering, and, of course, the NCI. So Roswell Park did a broad-based phase I study. Jim Holland was there at that time. He has unfortunately subsequently passed away. He was one of the real pioneers and also a past ASCO president. So among the patients in that phase I study were 11 patients with testes cancer. And there were three complete remissions and two partial remissions. And even in 2019, if we saw that with the phase 1 novel agent, there would be a tremendous amount of enthusiasm generated. We also looked at some of the preclinical work with platinum. And it is a drug that can cause testicular atrophy. In my youthful ignorance, I didn't realize that there are many drugs that cause testicular atrophy. So with that as a background, in 1974-- and I was on the faculty for one year at that time-- we wrote a protocol to simply add platinum, a novel experimental drug, and added it to the established two-drug regimen that I learned about when I was at M.D. Anderson, namely vinblastine and bleomycin. And the principles of combination chemotherapy aren't complicated. We want each drug to have single agent activity, different mechanism of cytotoxicity, different toxicity, and platinum as a non-mild suppressive drug, which can be given in full dosage, with vinblastine as a mild suppressive drug, and evidence of synergy. And one of the unique characteristics of platinum is it is synergistic across a panoply of cytolytic agents. So we started to study in the late summer of 1974 as a phase II study. And so we treated 47 patients when we first presented this data at the American Urological Association, later at ASCO. And I would be the first to admit that I was as startled as anyone that we were able to literally have a one logarithmic increase in the cure rate, because most progress in oncology is going from a 5% to a 10% to a 15% long-term survival rate. But all of a sudden with this three-drug combination, 60% of these patients were not only complete remission, but durable complete remission and cures. There was a lot of toxicity with platinum. And over the years, we learned, as science tends to learn, when a drug is active to mitigate the side effects as far as nephrotoxicity and nausea and vomiting. And we made modifications to the treatment regimens as the years went by, as you know, with changing the dosages have vinblastine, lowering the duration of maintenance therapy, and eliminating maintenance therapy, reducing the number of courses of platinum, substituting etoposide for vinblastine to where it's now the standard, bleomycin, etoposide, platinum, or BET. And I will make a final comment, in my long career, that this was a very exciting time in 1974. There were several chemotherapy drugs that were experimental drugs, such as doxorubicin and even a nitrosourea the first drugs to have penetration into the blood brain barrier. But the era of chemotherapy is gone and appropriately so. And science and medicine has moved forward. And now, we look at molecular targeted agents and immune checkpoint inhibitors and immunooncology. And that's what is exciting, so much more exciting about the field in 2019 than it was in 1974. But nevertheless, platinum has had legs. In 2019, it is still first line therapy in 12 different types of malignancies. Of course, testis cancer being the poster child for curable cancer. And I often mention that just as platinum has cured thousands, tens of thousands, hundreds of thousands of young men with cancer, testicular cancer saved platinum, because if it weren't for those early studies showing activity of platinum, I think I can say without fear of contradiction that the drug wouldn't be around right now because of this tremendous toxicity in the early phase I studies. Yeah, Larry, let me ask about that, because in the early 1970s when-- I wasn't around, but you didn't have antiemetics. You didn't have drug fractures. You didn't really understand the renal toxicity. Just briefly, how did you get around those? How do you get people-- I'm going to ask John the same question in a minute. What were you thinking, John? John is the recipient of our ignorance in that era. So taking it one item at a time. Platinum is a heavy metal. And we were somewhat slow in realizing that other heavy metals, like mercury, can cause acute tubular necrosis. And so when patients were getting platinum, as is true in those days, they would often just get IV pushed platinum. And so we learned that in order to prevent acute tubular necrosis, we needed to make sure that patients were well hydrated with IV saline solution before they start chemotherapy. We then give the intravenous platinum and then follow that with intravenous saline hydration, so that the drug doesn't accumulate in the proximal tubules, and we force a diuresis. And we never needed mannitol. And some people back then, in fact, perhaps even now, are doing the silly thing of mannitol diuresis, which is totally unnecessary. And so back in the early days before we had antiemetics, everyone had to be treated as an inpatient because we had to give 24-hour continuous hydration because of the [INAUDIBLE] from severe nausea, vomiting, and dehydration that would happen. Of course, today, it's all done as an outpatient with three or four hours of hydration. As far as nausea and vomiting is concerned, one of our first studies we published in The New Journal of Medicine was a cannabinoid derivative from Eli Lilly, called nabilone. And so nabilone, didn't produce a marijuana-type of high. It didn't cause euphoria. It caused some dysphoria and had a variety of side effects. But it lowered the incidence of nausea and vomiting. But what revolutionized chemotherapy induced nausea and vomiting, and ASCO recognizes this as one of the five leading advances in the past 50 years, was the discovery of the first 5-HT3 receptor antagonists. And this was a rational, selective pharmaceutical development. And this truly changed the face of how we give chemotherapy with drugs like platinum. Instead of having an average of 10 to 12 emetic episodes on day 1 of platinum, today with appropriate anti-emetics, the median number of emetic episodes is zero. People still get nausea. People still get occasional vomiting. But everything is done as an outpatient now. And it's done as an outpatient because of the discovery by others of what is the mechanism with platinum, which is not a gastrointestinal mechanism, but affects the emetic center in the medulla oblongata and the chemo receptor trigger zone and finding that patients get drugs like platinum, they get high level of 5-HT3. And developing a selective 5-HT3 receptor antagonist change the field completely. And, of course, now we also [? weigh ?] a methasone and neurokinin-1 antagonist, aprepitant or fosaprepitant. And we also have olanzapine as far as the nausea issue. And olanzapine is probably the best drug for nausea. So patients today have no concept of what patients like John went through when we had no knowledge about any of this whatsoever. And we were looking at things kind of naively by 2019 standards. I don't think I'm making this up. I recall as a medical student walking down the inpatient at University Hospital and thinking this smells just like my fraternity house. Without the fun involved. Yeah. And I got a kick now out of the so-called medical marijuana. But didn't you talk the administration into looking the other way for a while so that these guys could do that? Sort of. What had happened with nabilone, it had to be under lock and key, as if it were gold at Fort Knox. When we had an audit by the FDA and we had-- I don't know how many, I think 60 or 70 patients on nabilone, you know, we had to make sure we had every consent form and every safety guarded and everything. You know, here, we're using these incredibly toxic chemotherapy drugs and there was no regulation at all. And here we're using a pill to lessen nausea and vomiting, and it was just the hoops you had jump through were tremendous. When did you start realizing you had something big. Was it, you know, after two, three patients, or later-- Well, again, when you're young and dumb, it's easy, because you treat someone like John and you get the first chest X-ray three weeks later and things are gone and with pulmonary metastases. And you naively think, not only this cool, but, gee, that's great, it's not going to come back again. But we know even 40 years later that most epithelial malignancies that we get nice remissions with, the disease does come back again. So we had initial enthusiasm that platinum vinblastine myosin was a very active, but very toxic regimen. And we had the hope that this might be durable remission. And, Dan, I actually first presented data with testes scores, not at ASCO, but with the Annual American Urological Association meeting, and that was 99% urologists there. And so we had 20 patients that we had treated. And then that following year, I submitted an abstract to ASCO. And back then, it wasn't done online. We would send a paper abstract with a self-addressed postcard that they would send back to us whether it was accepted or not. And so when I sent in the abstract, I get the postcard back saying it was accepted as a plenary session paper. And I had no idea what plenary session even meant. It's true. And we get this postcard back in January for this June meeting. And all of a sudden my naivete went away, and I thought what, if I make a fool of myself? And I had this initial abstract with these complete remissions, and by the time June rolls around every one of them would have relapsed, which I was starting to learn happens in other tumors like small cell lung cancer, that are chemo sensitive disease. But fortunately, the time of presentation everyone was still disease free. And, of course, everyone for the most part remain disease free. So we had the first glimpse of activity with the first few patients. But it really wasn't until patients were out at a year that we really had the realization that these were not temporary remissions, but these were durable. And as it turned out, permanent remissions and cures. I wasn't there, but I understand that after you recorded that it looked like you had change the ratio of [? puranoctur ?] from 10%, 90% to 90%, 10%, that people in the audience, you had a standing ovation at the end of your presentation. Yeah, it was very heartwarming. It's literally the walk on the moon type of things is the things that you do once in your career, you know, that you never forget about. I had the opportunity to do that and not one of those four NCI cancer centers, but little Indiana University with our faculty of three. And we had one oncology nurse at that time, Becky Furness. We had no data managers. We had no compliance office or anything else. And we were giving [INAUDIBLE] back in the 1970s. I'd like now to turn briefly to your relationship with John Cleland. John, can you give us a brief history of your cancer treatment before you and Dr. Einhorn decided to go with the cisplatin. I was a student Purdue University, the fall of 1973, when I discovered I had a lump on the my left testicle. And I went to a local urologist. And he examined me on a Tuesday afternoon, in the middle of November, and told me he wanted me at the hospital the following morning. And the following day after that, they performed surgery. And I was diagnosed with testicular cancer. That was November 15, 1973. On the 29th of November then, I had a retroperitoneal node dissection. That was at the UI Cancer Center by Dr. John Donohue. And then on December 3, 1973, on a Monday morning, Larry Einhorn walked into my hospital room. And that was my first introduction to Dr. Einhorn. He talked to me a little bit and said we were going to put me on a 5-day course of a drug called mithramycin. We took mithramycin for five days. And then a couple of days after that, I was released from the hospital. So that was in the 1st of December of 1973. The middle of February of '74, I returned to IU Med Center just for a routine checkup. And I was diagnosed there again with testicular cancer had returned. And Dr. Einhorn began putting me on a three-drug regimen-- adriamycin, bleomycin, and [INAUDIBLE]. And I was on that until about July of '74. Then I was on actin myosin-D for a couple of months. And then we ultimately started in on the cisplatin in early October of '74. You have to tell us the story that you actually had to tell Dr. Einhorn about cisplatin because of a radio show you listened to. Well, by the middle of the summer, I had been pretty beat up, after all the chemotherapy and the nausea and everything. And I didn't really have a job-- or I couldn't do a job or anything. So most of the time, I just lay on the couch in our apartment and listened to the radio or watch TV. And one day-- I really like Paul Harvey-- and he came on the radio every day at noon there in Lafayette, Indiana. And one day he begins talking about researchers at Michigan State University. have maybe come up with the cure for cancer. So I begin listening much closer. And they talked about this chemotherapy called cisplatin. So I just made a mental note to myself, well, the next time I go see Dr. Einhorn, I'm going to ask him about this. Well, a couple of weeks later, I'm down at IU. And he's palpating me and listening to my chest and all this type of thing, you know. And I began asking him about that. And he said, John, just don't get too excited about that. We've heard of these cancer cures before. Probably nothing important has happened here. Don't worry about it, you know. And then two or three months later, I'm taking it. So that was my introduction, Dan, to cisplatin. Well, I can't to you-- Some of those Purdue graduates are pretty smart every now and then. We get lucky, like a blind squirrel. I just say, I can't tell you how many-- probably 100, 200 patients will told me things like this. And I've said exactly what Dr. Einhorn said to them, yeah, yeah, yeah. I wonder how many cures I've missed. OK, and the second story I want you tell us, John, is about your readmission to the hospital after your first cycle of chemotherapy. Yeah, I started this platinum October 7, 1974. I had five doses in the hospital. And then I was released. That was on October 7. October 20 rolls around, which was a Sunday, and I was violently ill. I had a fever of over 104, almost 104 and 1/2. And I was just completely almost derelict. My wife and a couple of friends, we contact Becky first, us my oncology nurse. And I guess she called Dr. Einhorn. And he said, well, come on down and check in through the emergency room at IU. And so that's what we did. We got there late at night, 9:30, 10:00 at night, something like that. And they always-- if I went to the emergency room, they always took a chest X-ray, which they did. And then in the hospital overnight and middle of the next morning, I see Dr. Einhorn and Becky getting off the elevator. My room was kind of in a corner. I could see part of the lobby out there and the elevator and the nurses station. And I could see them kind of go past the nurses station. And I could just tell that something was up. Somebody had good, let's put it that way, just by their body language, and the way they looked at each other and talked and walked. And they kept coming closer and closer and closer to my room. And finally, they walked in. And Dr. Einhorn says, John, your chest X-rays are clear. That's really good news. And, you know, I kind of interpreted that as, hey, I'm cure, you know. And ultimately, I guess I was, because from that chest X-ray the night before, my chest film was-- the weak before, my chest film was just riddled like Swiss cheese. And then the film was totally clear. You probably don't know this, but I've seen your chest x-rays, which is probably illegal now. Probably did a lot of illegal things back then. And, you know, that's when the scales fell from my eyes and I said, I'm going to be an oncologist. This is unbelievable. But, you know, I think to emphasize, it wasn't clear you were going to survive that weekend. To survive, you would be cured. But that goes back to how toxic this drug was at the start. Right. Right. It was not a lot of fun. I know that. Yeah. Well, I want to get back, Larry, to you for a moment, because there were two people in your life who were really essential to this story. One, of course, was Dr. Donohue, with whom you have published the, I think, seminal and classic paper in the annals of internal medicine. You want to say a few words about John. And the other is I'd love you to talk a little bit about Steve Williams. Steve was a fellow when I was a med student that I used to tease-- I mean, he's the only guy I ever knew who went from being a fellow to cancer center director I think in one year. I'm making that but-- he kept saying, you know, I might as well put me on faculty because he doesn't have any other fellows. Sure. So when I joined the faculty in 1973, in July of 1973, as I mentioned, I was the first oncologists. There were two hematologists there. And John Donohue is a true gentleman, one of the world leaders in urological oncology and the urological transplant with kidney transplant and many other fields. His ability to surgically cure patients with extensive retroperitoneal disease was known worldwide. And because of who John was and the fact that there were very few oncologists in the state of Indiana treating solid tumors, when he would see patients who would relapse after a retroperitoneal lymph node dissection, he would give chemotherapy himself, usually with actin myosin-D, which, by the way, causes almost as much nausea and vomiting as platinum did. And when I first got there, I knew John by reputation, but not by his interpersonal relationships with others. And with some fear and trepidation, I walked into his office because I told him I wanted to start looking at clinical trials in testes cancer. And I thought we might have a turf battle because he was treating patients with chemotherapy himself. And he just welcomed me with open arms. And he was so enthusiastic about finally having a partner and someone to collaborate with. And we had a wonderful, 30-plus years of collaboration with many important discoveries that John made equally, as I did. And, unfortunately, after John retired, he subsequently died when he was in Florida. And it's a similar sad story with Steve Williams. So Steve Williams was in my third fellowship class, which means we had one fellow a year. He was great, very humble, from Bedford, Indiana. And father was a newspaper reporter from the small town newspaper. And Steve was the eternal optimist. And to show you what an eternal optimist he was, when the Indianapolis Colts would those 14 games in a row, he always knew they going to win the next game, you know. And that's Steve. And John Cleland talking about Paul Harvey, Steve would have believed that platinum was going to be the cure too, you know. He was just a very positive person. And Steve was very gifted. He has a great relationship with patients. And there's not a person, a doctor, nurse, or patient, who has ever said anything unkind about Steve. He's one of the kindest people that we ever had the privilege of knowing. And Steve was very much involved with our testicular cancer research studies and many other pivotal studies as well. We decided to be a NCI cancer center, which is an enormous amount of work. And by then, we had about 10 faculty members in hematology, oncology. And no one wanted to do it. And so we went up to poor Steve and said, boy, Steve, this would be a great career move for you-- without telling him how much work is involved. We are cancer center today because Steve Williams made us a cancer center and everything that goes along with that. And before leaving, and fortunately, we're talking about John being cured with fourth line therapy with platinum combination chemotherapy, whereas if John had had that disease diagnosed a year earlier, quite honestly, John, you wouldn't be alive right now. And it's sort of the opposite for Steve Williams. He eventually developed metastatic melanoma before any of the marvels with immunotherapy or even the BRAF inhibitors were around. And he eventually died from these diseases that he fought so hard to palliate and prolong survival and cure with metastatic melanoma. And now there's a 30% cure rate-- 30%, 5-year survival and continuous 5-year survival with single agent PD-L1 inhibitors. And I want to make a final comment about John. And if this were 2019, rather than 1974, and you're looking at a patient who has been through mitramycin, which is used by me as adjuvant therapy briefly for adenocarcinoma, which is what John had, and then going through actin myosin-D and all the toxicity with that drug and then gone through a adriamycin combination chemotherapy, and looking at fourth line therapy. So when we started platinum combination chemotherapy, and John his fourth line therapy, yes, his chest X-ray looked like Swiss cheese, as he mentioned, but he was pretty much asymptomatic. And the courage and fortitude that it takes to go through treatment like this, because we knew what the side effects were with platinum. It had been around for about eight months, and we knew about all the horrendous side effects of the drug. We had no idea whether this would produce as fourth line therapy any prolongation of survival or any meaningful quality of life. And to go through this therapy without any idea whether it's going to help you, but to do it with truly altruistic motives and knowing that maybe this will help other patients in the future is really noble and admirable. And this is why John over the decades has been such a role model for clinical trials and for the cancer patient population. And I want to follow up. John, briefly, tell us about your history since then-- your family, your athletics, your career. I think it's inspirational, frankly. Well, I worked for the animal science industry for five years following my cure. And I decided finally I needed to give something back a little more to society than what I was actually doing. So I knew I wasn't smart enough to be a medical doctor. Male nursing wasn't exactly in vogue at that time, which might have been honestly a pretty good job for me. So I thought, well, I could be a teacher. I can teach life sciences. So background is pretty much life sciences in agriculture. So I did. I turned to teaching and teaching biology for 31 years and did a lot of coaching of track and cross country. And my wife and I have three kids. I married my college sweetheart even before I had testicular cancer. And, you know, I owe her just about everything in life. She hung in there with me when times were really dark. And I say we got three kids. And I've had great job and great career and friends. I want to emphasize you've had three children since your treatment. I also want to emphasize I know you've run one or two marathons since your treatment. Actually, Dan, I ran four marathons. So you ran four marathons since your treatment. Four full marathons, yes, sir. And I believe that your baseline creatinine is something like twice normal. And, Larry, you probably know this better than I do. But, again you've been inspirational to all of us. Well, thank you. Thank you, Dan. I'll tell you this. Every day I live is a blessing. I should have probably died 44, 45 years ago. I could drop dead at the end of this telephone conversation and have no regrets in life whatsoever. Well, John, you keep thinking that maybe one day you'll live long enough to see Purdue win the NCAA, but I wouldn't count on it. I was going to make a point, it must pain him truly to thank two guys from Indiana and also be appreciative of Michigan State, you know, for a guy from Purdue that must really be painful. Well, yeah, you know, testicular cure is basically Big 10 centered with Michigan State coming up with this cisplatin and Dr. Einhorn being on the IU you faculty. But it took a Purdue Boilermaker to be tough enough to handle all that to begin with, you know. That's true. OK, we're running out of time. I need to bring this to an end. I want to thank both of you again, both of you're inspirational, John for all the things we've talked about and Dr. Einhorn for so many of us who've gone into the field that we've trained and even the ones we've never touched directly, you touched hundreds of thousands of oncologists around the world indirectly. So thanks for all your contributions and what you've done. And thank you both for being on this podcast. I hope it opens up more inspiration for other young investigators and other young oncologists who don't really realize how we got where we are. So with that, we'll end this. And thanks a lot. And hope you have a nice weekend. OK, thanks, everyone. Have a good rest of the week. Bye, bye. Until next time, thank you for listening to this JCO's "Cancer Stories, The Art of Oncology" podcast. If you enjoyed what you heard today, don't forget to give us a rating or review on Apple Podcasts or wherever you listen. While you're there, be sure to subscribe so you never miss an episode. JCO's "Cancer Stories, The Art of Oncology" podcast is just one of ASCO's many podcasts. You can find all the shows at podcast.asco.org

If you thought porn originated in 1972 or 2017 or with the invention of the pizza delivery man, goodness madam are you mistaken. We’re reading John Cleland’s Fanny Hill (1748/49), which reminds us that porn has existed ever since the media to make it have been around (see also: the very hornt paintings from Pompeii ca. 79 CE). Our young heroine Fanny boinks her way through this touching novel, revealing a staggering knowledge of profuse pubes and metaphors for penetration. We discuss the bildungsroman, sex and commerce, eighteenth-century liberal philosophy, John Locke, and John Cleland being a shameless size queen. We also feel the need to mention that this is a listener request, and we take those extremely seriously except we still won’t read Infinite Jest so don’t ask. We read the Oxford edition edited by Peter Sabor. For a landmark account of the interlinkages between eighteenth- and nineteenth-century pornography and philosophical discourses, see Frances Ferguson’s Pornography, the Theory: What Utilitarianism Did to Action. Find us on Twitter, Instagram, and Facebook @betterreadpod, and email us nice things at betterreadpodcast@gmail.com. Find Tristan on Twitter @tjschweiger, Katie @katiekrywo, and Megan @tuslersaurus.

This week BTCC chief Alan Gow joins the V8 Sleuth Podcast powered by Timken. In Part 2, Alan talks about the Super Touring era and the years it was pitted against V8 Supercars in Australia, his long relationship as friend and manager to James Courtney, plus he tackles your National Motor Racing Museum Couch Racer Questions and the MotorFocus Top 10 Shootout.

In this episode we go back to the 18th century to look at the first Western erotic novel, the aptly titled Fanny Hill. Within the pages we discover that thigh sex is a thing and that the 18th century had a lot of fun words for genitalia. Give it a go with your lovers, spice up your dirty talk and report back.*Content warning* this episode contains references to rape. For those looking to check our academic sources or for further reading (you nerdy, saucy minxes!):Weed, David. "Fitting Fanny: Cleland's" Memoirs" and the Politics of Male Pleasure." In Novel: A Forum on Fiction, vol. 31, no. 1, pp. 7-20. Duke University Press, 1997.Fisher, Will. "“Wantoning with the Thighs”: The Socialization of Thigh Sex in England, 1590–1730." Journal of the History of Sexuality 24, no. 1 (2015): 1-24.McCracken, David. "A Burkean Analysis of the Sublimity and the Beauty of the Phallus in John Cleland's Fanny Hill." ANQ: A Quarterly Journal of Short Articles, Notes and Reviews 29, no. 3 (2016): 138-141.Lubey, Kathleen. Excitable Imaginations: Eroticism and Reading in Britain, 1660-1760. Rowman & Littlefield, 2012.Music: Yesterday's Secret by texasradiofish (c) copyright 2018 Licensed under a Creative Commons Attribution Noncommercial (3.0) license. http://dig.ccmixter.org/files/texasradiofish/57365 Ft: Mr. Yesterday, ElRon XChile, Electronico, Duckett, DJ Stupid, robwalkerpoet, Richard Kilmer, inchadney, Sven Erga. Our GDPR privacy policy was updated on August 8, 2022. Visit acast.com/privacy for more information.

Let's talk about sex, baby. Join us for the first episode of PhDrunk, where we drink adult beverages and discuss a book with lots of adult content. This episode is brought to you by euphemisms, the purity myth, and nine years of longing. --- Support this podcast: https://anchor.fm/ph-drunk/support

Welcome back to another episode of Liberty Revealed, the show dedicated to revealing personal liberty to all who listen. I am your host, Mike Mahony, and today I want to talk to you about censorship.What exactly is censorship? Defining this term properly will help you decide if it is ever a good thing. Censorship is the coercive silencing of dissenting views by political authorities generally in order to protect an official orthodoxy or to prevent the spread of ideas not authorized by the powers that be. As Alberto Manguel writes in A History of Reading, censorship “is the corollary of all power, and the history of reading is lit by a seemingly endless line of censors’ bonfires.”It should be noted that censorship has been and continues to be a common feature of oppressive regimes. John Milton, whose Areopagitica (written in protest of the censorship of his writings on divorce) remains the most eloquent defense of the free press written in English, provided a history of censorship from 411 B.C., when the works of Protagoras were burned in Athens on the grounds that they taught agnosticism. In the Republic, Plato advocates censorship of poetry and music that fail to promote the state’s interests. This tradition has continued in modern times. Beginning in 1933, Josef Goebbels oversaw mass book burnings, which became a trademark of the Nazi regime. In the Soviet Union, an agency called Glavlit oversaw all printed publications, including even food labels, to prevent the dissemination of unacceptable material. Today, officials in China, Saudi Arabia, Pakistan, and other countries have implemented censorship of books, periodicals, television, radio, and the Internet to ensure that political dissent, religious heterodoxy, or sexually provocative material are not disseminated to the general public.The introduction of the printing press and the Protestant injunction for believers to read the Bible for themselves made censorship an increasingly important subject of debate in Reformation Europe. In 1559, the Catholic Church issued the first Index Liborum Prohibitorum, which lists books forbidden as dangerous to the faith; the Index was not eliminated until 1966. Protestant nations were no less censorious. Henry VIII ordered the burning of Reformation books prior to his own break with Rome, including English translations of the New Testament, and established the licensing requirement for publishing that Milton would protest a century later in Areopagitica.In the ensuing decades, the English common law gradually developed a principle of free expression that barred the government from engaging in “prior restraint” (i.e., the forcible prevention of publication). But no rule protected authors from punishment after publication. Thus, although William Blackstone explained in his Commentaries that the prohibition on prior restraints was of the essence to English liberty, there was no “freedom from censure for criminal matter when published.” Dissidents could print their views, but the threat of prosecution for “seditious libel” and other political crimes helped temper criticism of the government. In America, however, the famous 1735 acquittal of John Peter Zenger largely eliminated seditious libel as a threat to colonial printers. Prosecutions for the publication of indecent material did continue, however. The first book to be banned in the United States was John Cleland’s pornographic novel, Fanny Hill, or Memoirs of a Woman of Pleasure, which was prohibited in Boston in 1821 and, when republished in 1964, was again banned, leading to an important Supreme Court decision defining obscenity.Because the common law defined freedom of the press by the absence of prior restraints, the 1st Amendment to the U.S. Constitution, which protects the freedoms of press and speech, has been interpreted as an almost absolute prohibition on prior restraints. Some have argued that the 1st Amendment goes no further, whereas others contend that it goes further than common law and prohibits certain forms of post-publication punishment or other government actions intended to limit the dissemination of information. American courts have identified three broad categories of censorship other than prior restraint: (1) the punishment of those who produce material—such as obscenity or extraordinarily intimidating threats—which is determined not to qualify as “speech” or “press” as the terms were understood by the authors of the 1st Amendment, (2) the use of libel and slander to punish those who utter falsehoods or unflattering comments, and (3) the removal of books from public libraries.It is widely conceded that certain material is so obscene that it contains no ideas or expression worthy of constitutional protection. However, defining the word obscene has proven extremely difficult for courts because too broad a definition might well threaten the dissemination of provocative, but serious, material. In 1973, the Supreme Court defined obscenity as material that, taken as a whole, appeals to the prurient interest in sex, that portrays sex in a patently offensive way, and that lacks serious literary, artistic, political, or scientific value. This definition has proved difficult to apply, and in recent decades, governments in the United States have largely given up the efforts to ban pornography. Worse, it can be dangerous to declare that certain forms of expression are not protected forms of speech. Prohibitions of “hate speech,” or of expressive actions thought to be extraordinarily offensive, such as flag-burning, are similar in that they can often be justified on the grounds that such forms of expression communicate sentiments that are unworthy of legal protection. The dangers of such a rationale are evident in the area of sexual harassment laws, which in recent years have been expanded so as to intimidate some speakers or to prohibit some forms of expression that, whatever their merit, are clearly communicative and not obscene or threatening. In addition, this effort to define certain categories of expression as outside constitutional protections has spawned legal theories that seek to define certain categories of speech as deserving “lesser” constitutional protection. This regime of diminished protection prevails in the realm of commercial speech, defined to be speech that proposes a commercial transaction. Although the Constitution provides no warrant for such discrimination, the Supreme Court has found that commercial expression can be extensively regulated because it is not considered part of the political or cultural dialogue thought essential to democratic decision making. Likewise, campaign finance regulations, although often restricting the rights of individuals to express their political preferences, are frequently defended on the grounds that limiting the expressive opportunities of wealthy groups fosters broader democratic debate.Libel and slander laws have regularly been abused to stifle criticism of political authorities, but in the United States these efforts were severely curtailed by the 1964 Supreme Court decision New York Times v. Sullivan, which held that “public figures,” such as government officials or those who choose to partake in matters of public concern, can only rarely prevail in libel cases. Even publication of obviously false and obscene material about a public figure has been held protected by the 1st Amendment, as when pornographer Larry Flynt successfully defended his right to publish a counterfeit interview suggesting that minister Jerry Falwell had lost his virginity to his mother in an outhouse. Although public figures can virtually never succeed when suing media for such libel in the United States, European countries, particularly England, do not prohibit such suits. As a result, criticism of political figures in England is still often hampered. Worse, because publications produced in the United States are easily available in England, public figures who have been criticized have brought suit against American writers in English courts and recovered, although these suits would be constitutionally barred under American law. This “libel tourism” has become a matter of increasing concern in the age of the Internet.One common source of debate over freedom of expression in the United States involves the removal of controversial books from public libraries and libraries in public schools. Although not strictly a form of censorship—because the publications remain legal and available elsewhere— such attempts to prevent reading are common and are monitored by the American Library Association’s Office of Intellectual Freedom. The U.S. Supreme Court has never ruled that such removals are prohibited by the 1st Amendment, but in Board of Education v. Pico, a plurality of justices held that while school boards have broad discretion to choose what books are appropriate for curriculum or classroom use, and to choose what books may be placed in a library, they may not remove books that are already in the library on the basis of the ideas contained in those books or in an attempt to prescribe orthodox opinions.To me, it would appear that the vast majority of censorship is bad. I feel like going down the path of allowing censorship is an extremely slippery slope that leads to some very dangerous situations. If you allow censorship of things you define as bad, what stops others from defining as bad things you see as good? How do we determine what does and does not get censored? Perhaps we should use similar standards to our libel and slander laws? Many look towards protecting children as a good reason to censor things. Marjorie Heins does not argue that unfettered access to all forms of expression would benefit children. Even as some studies have claimed that violent images may help create violent children, Heins cautions against simplistic conclusions. “When you look at it, the definitions of violent entertainment are all over the lot,” she said. “There’s very little attempt to put violence in context, so it would be impossible to frame any kind of censorship legislation that would pinpoint what the harm is.”Rather than “intellectual protectionism,” Heins advocates media literacy programs and sexuality education to help children cope with their surroundings. She also questions the efficacy of “forbidden speech zones,” which may attract children to the very material that adults would deny them. Better, she said, to teach children to make the best choices than to pretend those choices don’t exist.“Kids are going to make some choices about culture, and those choices can be influenced by their interaction with their parents and their teachers,” said Heins. “It’s sort of similar to food. I think when your kid is a baby you can feed them good healthy baby food. Once they get into nursery school, they’re going to start learning about the other temptations, so the most parents can do is to try to continue to make some rules and try to explain why they’re the right rules.”Heins concludes that concerns about violence, language, and sex “have more to do with socializing youth than with the objective proof of psychological harm.” Censorship on behalf of children, she believes, is really done for the adults who demand it.I have to agree with Heins. We don’t censor to protect children, we do it because adults demand it. I say we should handle this very carefully. We should consider that the vast majority of censorship is simply wrong and should not be allowed. Tell me your thoughts on this by leaving a voicemail on the Yogi’s Podcast Network hotline at (657) 529-2218.That’s it for this episode of Liberty Revealed. .If you like what you’ve heard, please rate us 5 stars on Apple Podcasts and Google Play. If you’d like to learn more about personal liberty, grab your free copy of my book “Liberty Revealed” by heading over to http://yogispodcastnetwork.com/libertyrevealed. Until next time...stay free!

Up to 25% of the world’s carbon emissions can be offset through natural climate solutions, and the #1 channel, both domestically and internationally, is reforestation. Planting trees is obviously a huge market opportunity. But the question is, how do we pay for it?    Mike Smith and John Cleland are the managing partners of RenewWest, an environmental services company committed to replanting forests in areas burned by wildfire in the American West and financializing the practice through carbon offset markets. On this episode of Reversing Climate Change, Mike and John join Ross and Christophe to share the team’s three-phase process and explain why reforestation projects are typically disfavored in traditional carbon markets.   Mike and John describe the top challenges forests face, including climate change, disease and fire, and introduce us to the concept of assisted migration risk. Listen in to understand why a Timber Investment Management Organization, or TIMO, Fund is a better way to raise capital for reforestation than private equity and learn how RenewWest is navigating the intersection where ecology and finance meet!    Key Takeaways   [1:36] Mike’s path to reversing climate change Witness fire on 44K acres in Idaho as kid, bare soil persists RenewWest tackles connection between climate + forestry   [3:39] John’s path to reversing climate change Career in Chicago as commodities trader, launch brokerage Shift to impact investing (opportunity in carbon markets)   [9:29] What Mike & John do at RenewWest Find areas burned by wildfire Work to develop as carbon offset projects   [12:11] The RenewWest three-phase process Discovery—meet with landowner, create LOI Pre-development (includes carbon analysis) Raise capital and plant   [16:12] Why reforestation projects are disfavored in carbon markets Factor of additionality No offset until sequestration happens   [25:10] Venture capital vs. TIMO funding Reforestation doesn’t fit VC timeline, return expectations Long-term play of fund attracts institutional investors   [29:18] The top three challenges forests face Climate change, disease and fire All problems defined by water   [36:40] The obstacles reforestation is up against Carbon markets not seen as investible opportunity Requires long-term investment in green infrastructure Political divisiveness around carbon pricing   [47:44] The concept of assisted migration risk Climate change faster than natural systems adapt Same trees won’t survive (move north or uphill)   [50:57] What John & Mike would like to fix about carbon markets High transactional costs Easier to fund reforestation vs. project development   Connect with Ross & Christophe    Nori Nori on Facebook  Nori on Twitter Nori on Medium Nori on YouTube Nori on GitHub Nori Newsletter Email hello@nori.com Nori White Paper Subscribe on iTunes Carbon Removal Newsroom   Resources   RenewWest Email msmith@renewwest.com  Nori Lightning Sale Techstars Impact Finance Center Phil Taylor on RCC EP091 Climate Action Reserve California Water Action Collaborative California Environmental Quality Act Cleantech Open Greta Thunberg & George Monbiot Video Blue Forest Conservation California Compliance Offset Program 1990 Clean Air Act Amendment Benji Backer on RCC EP074 The Sixth Extinction: An Unnatural History by Elizabeth Kolbert

In 1748, the English writer John Cleland published the novel "Memoirs of a Woman of Pleasure," popularly known as "Fanny Hill." Cleland wrote Fanny Hill while he was confined in a London debtor's prison, and it is considered the first pornographic novel. It is an "epistolary novel," consisting of two letters from Fanny Hill to an unnamed friend, describing her youth as a prostitute.Fanny Hill was banned in England the year after it was published, but illicit editions soon appeared, and found their way to the United States. In 1821, Massachusetts banned the novel, and the Massachusetts Supreme Court affirmed its suppression.In 1963, Putnam published Fanny Hill as "John Cleland's Memoirs of a Woman of Pleasure." New York State Supreme Court Judge Arthur G. Klein held that it was not obscene under the Supreme Court's Roth test, but a Massachusetts court disagreed. Putnam challenged the Massachusetts ruling, and the Supreme Court eventually held that Fanny Hill was not obscene under the Roth standard in A Book Named "John Cleland's Memoirs of a Woman of Pleasure", et al. v. Attorney General of Massachusetts (1966).In 1963, Recorded Literature, Inc. also published "Memoirs of Fanny Hill: Unexpurgated Dramatization of the Famous and Classic Memoirs of a Woman of Pleasure" a 2xLP dramatic reading of Fanny Hill, performed by Pamela Hayes Marshall, Felicia Peters, Marcia Gatsby, and Audrey Long. It appears that the names of the performers were all pseudonyms. The gatefold of the album liberally from Klein's opinion finding the book not obscene. Unsurprisingly, this "unexpurgated" version of Fanny Hill was edited to focus on only the most prurient parts of the story.This is the track list for part 3:Mr. Norbert's FoolishnessFanny's InheritanceReunion With CharlesFanny's Farewell See acast.com/privacy for privacy and opt-out information.

In 1748, the English writer John Cleland published the novel "Memoirs of a Woman of Pleasure," popularly known as "Fanny Hill." Cleland wrote Fanny Hill while he was confined in a London debtor's prison, and it is considered the first pornographic novel. It is an "epistolary novel," consisting of two letters from Fanny Hill to an unnamed friend, describing her youth as a prostitute.Fanny Hill was banned in England the year after it was published, but illicit editions soon appeared, and found their way to the United States. In 1821, Massachusetts banned the novel, and the Massachusetts Supreme Court affirmed its suppression.In 1963, Putnam published Fanny Hill as "John Cleland's Memoirs of a Woman of Pleasure." New York State Supreme Court Judge Arthur G. Klein held that it was not obscene under the Supreme Court's Roth test, but a Massachusetts court disagreed. Putnam challenged the Massachusetts ruling, and the Supreme Court eventually held that Fanny Hill was not obscene under the Roth standard in A Book Named "John Cleland's Memoirs of a Woman of Pleasure", et al. v. Attorney General of Massachusetts (1966).In 1963, Recorded Literature, Inc. also published "Memoirs of Fanny Hill: Unexpurgated Dramatization of the Famous and Classic Memoirs of a Woman of Pleasure" a 2xLP dramatic reading of Fanny Hill, performed by Pamela Hayes Marshall, Felicia Peters, Marcia Gatsby, and Audrey Long. It appears that the names of the performers were all pseudonyms. The gatefold of the album liberally from Klein's opinion finding the book not obscene. Unsurprisingly, this "unexpurgated" version of Fanny Hill was edited to focus on only the most prurient parts of the story.This is the track list for part 3:Affair With Will (Cont.)Emily's AdventureHarriet's AdventureLuisa's Adventure See acast.com/privacy for privacy and opt-out information.

In 1748, the English writer John Cleland published the novel "Memoirs of a Woman of Pleasure," popularly known as "Fanny Hill." Cleland wrote the novel while he was confined in a London debtor's prison, and it is considered the first pornographic novel. Fanny Hill is an "epistolary novel," consisting of two letters from Fanny Hill to an unnamed friend, describing her youth as a prostitute.Fanny Hill was banned in England the year after it was published, but illicit editions soon appeared, and found their way to the United States. In 1821, Massachusetts banned the novel, and the Massachusetts Supreme Court affirmed its suppression.In 1963, Putnam published Fanny Hill as "John Cleland's Memoirs of a Woman of Pleasure." New York State Supreme Court Judge Arthur G. Klein held that it was not obscene under the Supreme Court's Roth test, but a Massachusetts court disagreed. Putnam challenged the Massachusetts ruling, and the Supreme Court eventually held that Fanny Hill was not obscene under the Roth standard in A Book Named "John Cleland's Memoirs of a Woman of Pleasure", et al. v. Attorney General of Massachusetts (1966).In 1963, Recorded Literature, Inc. also published "Memoirs of Fanny Hill: Unexpurgated Dramatization of the Famous and Classic Memoirs of a Woman of Pleasure" a 2xLP dramatic reading of Fanny Hill, performed by Pamela Hayes Marshall, Felicia Peters, Marcia Gatsby, and Audrey Long. It appears that the names of the performers were all pseudonyms. The gatefold of the album liberally from Klein's opinion finding the book not obscene. Unsurprisingly, this "unexpurgated" version of Fanny Hill was edited to focus on only the most prurient parts of the story.This is the track list for part 2:Abduction Of CharlesThe Landlady's OfferIncident With Mr. H.Affair With Will See acast.com/privacy for privacy and opt-out information.

In 1748, the English writer John Cleland published the novel "Memoirs of a Woman of Pleasure," popularly known as "Fanny Hill." Cleland wrote the novel while he was confined in a London debtor's prison, and it is considered the first pornographic novel. Fanny Hill is an "epistolary novel," consisting of two letters from Fanny Hill to an unnamed friend, describing her youth as a prostitute.Fanny Hill was banned in England the year after it was published, but illicit editions soon appeared, and found their way to the United States. In 1821, Massachusetts banned the novel, and the Massachusetts Supreme Court affirmed its suppression.In 1963, Putnam published Fanny Hill as "John Cleland's Memoirs of a Woman of Pleasure." New York State Supreme Court Judge Arthur G. Klein held that it was not obscene under the Supreme Court's Roth test, but a Massachusetts court disagreed. Putnam challenged the Massachusetts ruling, and the Supreme Court eventually held that Fanny Hill was not obscene under the Roth standard in A Book Named "John Cleland's Memoirs of a Woman of Pleasure", et al. v. Attorney General of Massachusetts (1966).In 1963, Recorded Literature, Inc. also published "Memoirs of Fanny Hill: Unexpurgated Dramatization of the Famous and Classic Memoirs of a Woman of Pleasure" a 2xLP dramatic reading of Fanny Hill, performed by Pamela Hayes Marshall, Felicia Peters, Marcia Gatsby, and Audrey Long. It appears that the names of the performers were all pseudonyms. The gatefold of the album liberally from Klein's opinion finding the book not obscene. Unsurprisingly, this "unexpurgated" version of Fanny Hill was edited to focus on only the most prurient parts of the story.This is the track list for part 1:Journey To LondonEncounter With Mrs. BrownRendezvous With CharlesChelsea Tryst With Charles See acast.com/privacy for privacy and opt-out information.

Nicole Kidman discusses her first lead role for some time as she plays a tortured detective in the grimy LA-set thriller, Destroyer.John Cleland's 18th century novel Fanny Hill has become known as 'the most famous banned book in the country'. Written in 1749, it tells the story of Frances ‘Fanny' Hill who, after her parents' death, travels from the countryside to London earning money as a sex worker. As one of the oldest-known copies is set to go under the hammer, literary critic Sarah Ditum discusses if it still has the power to excite and shock us.Netflix's Tidying Up with Marie Kondo has caused a stir for suggesting that we should hang on to only 30 books that ‘spark joy'. Stig visits the author Linda Grant in her living room to ask her about famously culling the book collection that she'd built up from childhood.As Sotheby's prepare their auction The Female Triumphant, a selection of works by female Old Masters from the 16th to 19th centuries, including Artemisia Gentileschi, Sotheby's specialist Chloe Stead and critic Charlotte Mullins consider the role of - and the struggles faced by - women artists from that period and today.Presenter: Stig Abell Producer: Jerome Weatherald

On the Shelf July 2018 The Lesbian Historic Motif Podcast - Episode 24a Your monthly update on what the Lesbian Historic Motif Project has been doing. In this episode we talk about This month’s author guest is Justine Saracen Recent and upcoming publications covered on the blog The Zimmern Chronicle Brantôme’s Lives of Fair and Gallant Ladies “From Huw Arwystli to Siôn Eirian” by MIhangel Morgan, queer Welsh literature Primary source material for the study of 17th century English women Emma Donoghue looks at the intersection of the motifs of hermaphrodite and lesbian in 17-18th century England Clorinda Donato considers John Cleland’s translation of the life of Catherine VIzzani as a satirical attack on Mary Wortley Montagu Jacqueline Holler considers the trial confessions of a 16th c Mexican holy woman, heretic, and sexual outlaw Susan Lanser discusses the political implications of women’s same-sex relationships in 17th century England Tim Hitchcock looks at homosexual subcultures in 18th century England New and forthcoming books The Travels of Charlie by J.B. Marsden (Sapphire Books) Holding Their Place by Kelly Wacker (Bold Strokes Books) Shadow of the Phoenix by Rebecca Harwell (Bold Strokes Books) Thyra’s Promise by Natalie Debrabandere (self-published) Special non-historic shout-out: A Study in Honor by Claire O’Dell (Harper Collins) Ask Sappho: Sheena asks “Was there anything similar to drag king performers before the 20th century?” More info The Lesbian Historic Motif Project lives at: http://alpennia.com/lhmp You can follow the blog on my website (http://alpennia.com/blog) or subscribe to the RSS feed (http://alpennia.com/blog/feed/) If you have questions or comments about the LHMP or these podcasts, send them to: contact@alpennia.com A transcript of this episode can be found here. http://alpennia.com/blog/lesbian-historic-motif-podcast-episode-24a-shelf-july-2018 If you enjoy this podcast and others at The Lesbian Talk Show, please consider supporting the show through Patreon: https://www.patreon.com/TheLesbianTalkShow

Durante la historia se han producido innumerables casos de prohibición y censura de libros, llegando incluso hasta la quema de los mismos. Respecto a esto último el ejemplo más famoso fue el de la quema de libros durante el régimen Nazi en la Alemania de Hitler acaecido en el Bebelplatz en Berlín, el 10 de mayo de 1933. Aquéllos que se oponen a la quema de libros generalmente comparan este hecho con lo ocurrido durante el gobierno de los nazis. En cuanto a la censura se refiere Huckleberry Finn fue y ha sido objeto de repetidas prohibiciones en las escuelas debido al uso de la palabra nigger (negrata), término que en Estados Unidos ha adquirido un peso específico tan alto que incluso en los medios de comunicación se refieren a él como la palabra-n. En 1921, un tribunal estadounidense también declaró obsceno un pasaje del Ulises, de Joyce, y el libro estuvo prohibido hasta 1933. También sufrieron cortes y recortes Trópico de Cáncer, de Henry Miller, o Fanny Hill, de John Cleland. Incluso el cuento de la Caperucita Roja (de Charles Perrault, Peter Stevenson) estuvo censurado en dos escuelas del municipio de Empire, en California en el año 1990.

2 time British Touring Car Champion John Cleland chats at the Goodwood Revival 2017

[[:encoded, "2 time British Touring Car Champion John Cleland chats at the Goodwood Revival 2017"]]

Double touring car champion John Cleland joins the podcast team to tell his many stories from his racing career. See acast.com/privacy for privacy and opt-out information.

What is the difference between a love story and a romance? Which do you prefer?  We sat down at the Bryant Corner Café to talk about love. Valentines Day had everyone thinking about it, but we got into a pretty substantive discussion about the difference between love stories and romances.  Finally, different kinds of love, between different people emerge as our main theme.  Nancy started out, however, by calling our attention to a recently published novel she found remarkable by an author she follows.“A God In Every Stone,” by Kamila Shamsie, is the story of a young English woman who goes on an archeological dig in what would become Pakistan just before WW1 just breaks out. Nancy says, “What we get in this wonderful, wonderful novel is a perspective on WW1 from the Indian soldiers who went to fight for the British and died in great numbers.”  It is also a story of the beginnings of the fight for independence on the sub-continent.  She says it opens up a period of history as only fiction can, bringing new insights and revealing the roots of our present turmoil in the struggles of the past.  It is a challenging book for the way the story is told and for the subject matter, but she says it fabulous. Here are the books we talked about. Some are romances. Most are love stories.What do you think, what is the difference? “Gone With The Wind,” by Margaret Mitchell“Romeo and Juliet,” by William Shakespeare“Soulless” by Gail Carriger, a romance about a young woman who is rudely attacked by a vampire. Nancy loved it. “Astrid and Veronika,” by Linda Olson.  Sharon says two women, one young, one old, share a love, but not a sexual love.“Me Before You,” by JoJo Moyes. A young woman takes care of a wheel-chair bound man.  Nancy loved it because JoJo Moyes doesn’t give into the easy way out andturned what mighthave beenaromance into a love story.“Plainsong,” by Ken Haruf a love story between two old men and the young girl they care for.“Dancing Alone Without Music” by Larry Gildersleeve, who is a friend of Jenny’s. She says it’s an evolution of different loves.Diana Galbadon’s long and involved books. “Life After Life” by Kate Atkinson. Judy says it is about love within a family.“Boys In The Boat,” by Daniel James Brown.  Judy said that what amazed her was the love of Mr. Pocock for the boats themselves and the young men in the boat. So now, when defined so broadly, what book isn’t a love story? “Angle of Repose,” by Wallace Stegner, in which Nancy asks, who loves whom? ( well, she said “who loves who,” but you know how autocorrect can be.)  Another love story by this definition can be Stegner’s “Crossing to Safety.”“Still Alice,” by Lisa Genova“Cocoon of Cancer” An Invitation to Love Deeply,” by Abbe Rolnick with Jim Wiggins“Chocolat,” by Joanne Harris is Roz’s choice. That prompts Nancy to plug her other books, which she says don’t get the attention they deserve. She recommends “Gentlemen and Players.”“Like Water For Chocolate,” by Laura Esquivel“Bettyville,” by George Hodgman is the story of a son who leaves his life to take care of his 90 year old mother.  Susie says it is funny and delightful.“Cold Mountain,” by Charles Fraser“Atonement,” by Ian McEwan“Love In The Time of Cholera,” by Gabriel Garcia Marquez“Love Again,” by Doris Lessing. Not about romantic or erotic love,  but about the trembling between them says Elwyn. He also loves the episode in Tom Sawyer where he explores his passion of Becky Thatcher.“Infinity in the Palm of Her Hand,” by Giaconda Belli“Middlemarch,” by George EliotWrapping, we had shout outs for Louise Penny’s Inspector Gamache mysteries, Dorothy Sayers’ romance between Peter Wimsey and Harriet Vane and to get into the western genre, “Shane,” by Jack Shaefer about the love of a young boy for his father and the man who rides in to help.“Bridges of Madison County,” by Robert Waller, or “Fanny Hill,” by John Cleland, but now we are getting pretty far afield from love or even romance. These are but insubstantial flings, aren’t they?  

LONDON—Family planning is a key priority for fulfilling global development goals, according to researchers writing in a special series of The Lancet medical journal coinciding with the London Summit on Family Planning. Peter Goodwin hears from one of the Lancet authors, John Cleland, the London School of Hygiene & Tropical Medicine’s Professor of Medical Demography, about the impact family planning has on saving mothers, infants — and the planet.

For as long as man has had conscious thought, he has thought about sex, and this has certainly been reflected in his literary themes. From the literate but hypermasculine rememberances of Henry Miller's Tropic of Cancer, to the literate but impishly comedic creations of Voltaire's Candide to the not-at-all literate nor interesting fap material in John Cleland's Fanny Hill, erotic writing has had a storied history inside the pages of legitimate fiction. But fortunately, the English published Literary Review has helpfully highlighted some of the least impressive examples for us to lend our voices to. This week, the F Plus is on top of you, Skinner.

John Cleland discusses early trial findings about a myocin activator in the treatment of heart failure.